Document:

EX-10.11

 Exhibit 10.11 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE
REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 
 SUPPLY & LICENSE AGREEMENT 

This Supply and License Agreement (this “Agreement”), made as of September 1, 2020 (“Effective
Date”), is by and between BIOTIUM, INC. (“BIOTIUM”), a California corporation with a place of business at 46117 Landing Parkway, Fremont, CA 94538, and CYTEK
BIOSCIENCES, INC., a Delaware corporation with place of business at 46107 Landing Parkway, Fremont, CA 94538 (along with its Affiliates, “LICENSEE”). 

ARTICLE 1. BACKGROUND RECITALS 

BIOTIUM has expertise in the development and manufacture of fluorescent dyes, bioassay kits and other related research reagents. BIOTIUM has
developed a group of proprietary fluorescent dyes that are useful for in vitro and in vivo optical imaging, and is skilled in the manufacture of those fluorescent dyes and related reagents. 

LICENSEE desires to purchase certain Biotium Products (as listed on Exhibit A) from BIOTIUM to conjugate to proteins and/or antibodies and to
use such conjugates as a component in Licensed Products, and to obtain from BIOTIUM rights to market and sell Licensed Products to its End-Users and Distributors. 

BIOTIUM is willing to supply Biotium Products to LICENSEE and to grant LICENSEE rights to use Biotium Products to conjugate to proteins and/or
antibodies, all in accordance with the terms and conditions set forth in this Agreement. 
 Based on the foregoing recitals and in
consideration of the mutual covenants and promises herein contained, the Parties agree as follows: 
 ARTICLE 2. DEFINITIONS 

For purposes of this Agreement and all Exhibits attached hereto, the following terms shall have the meaning set forth below: 

2.1 “Affiliate” means, with respect to either Party, a person or entity, including without limiting the
generality of the foregoing, corporations, partnerships and joint ventures, that directly or indirectly through one or more intermediaries, controls, is controlled by or is under common control with such Party. “Control”
(and, with correlative meanings, the term “controlled by” and “under common control with”) means the possession of the power to direct or cause the direction of the management and policies of a person
or entity, whether through the ownership of voting stock, by contract or otherwise. In the case of a corporation, “control” shall mean, among other things, the direct or indirect ownership of fifty percent (50%) or more of
its outstanding voting stock. 
 2.2 “Agency” means any applicable Government Authority involved in
establishing or maintaining regulations, or granting approvals, for the manufacture of Products or the formulation or sale of Products. 

2.3 “Agreement” means this Agreement, as amended from time to time. 

2.4 “ASR” means Analyte Specific Reagents as defined by 21 CFR 864.4020 or any successor or replacement
definition or any foreign equivalent. 

  
 1 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT
IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 
  

 2.5 “BIOTIUM LICENSED PATENTS” means the Intellectual Property
Rights licensed to, owned, or otherwise controlled by BIOTIUM or its Affiliates, existing as of the Effective Date or thereafter, that relate to the manufacture, use, sale, or import or other commercialization of the Licensed Products, or
derivatives or combinations thereof, including but not limited to i) the Patents and Patent applications listed in Exhibit D, all Patents issuing from said Patents and Patent applications, and any divisionals, continuations and continuations-in-part, and reissues and reexaminations of any such Patents and Patent applications, together with all foreign counterparts of the foregoing; ii) know-how not generally available to the public but transferred to LICENSEE under this Agreement; iii) trademarks listed in Exhibit D, including any modifications that may be made thereto from time to time as
provided under this Agreement, and all associated trade names, logos, and product names, whether or not such trademarks are registered with the United States Patent and Trademark Office or other governmental body; and (iv) copyrights as
described in Section 13.4 (technical publications), whether or not such copyrights are registered with the US Library of Congress or other governmental body. 

2.6 “Biotium Product(s)” or “Product(s)” means the current, specific products
identified by BIOTIUM’s catalog numbers listed on Exhibit A attached hereto, a general description of which is set forth opposite each such catalog number. Biotium Products shall also include any such products as changed or modified by Biotium
in a manner that does not substantially alter the form, fit or function of any such product. 
 2.7 “Confidential
Information” of a Party means all materials, know-how or other information, including, without limitation, proprietary information and materials (whether or not patentable) regarding such
Party’s technology, products, business information or objectives, which is disclosed to the other Party and designated as confidential by the disclosing Party, including by letter or by the use of an appropriate stamp or legend, prior to or at
the time any such material or other information is disclosed by the disclosing Party to the other Party. Notwithstanding the foregoing to the contrary, materials, know-how or other information which is orally,
electronically or visually disclosed by a Party, or is disclosed in writing without an appropriate letter, stamp or legend, shall constitute Confidential Information of a Party if it would be apparent to a reasonable person that such information is
confidential or proprietary to the disclosing Party. Notwithstanding the foregoing, any technical or financial information of a Party disclosed by such Party to the other Party or disclosed through an audit or sales report shall constitute
Confidential Information of the disclosing Party unless otherwise specified. Confidential Information of a Party will also include all information disclosed by such Party under that certain Confidential Disclosure Agreement between the Parties dated
October 18, 2019 (the “CDA”). 
 2.8 “Deduction” means, in relation to the sale
to End-Users or a Distributor of any Licensed Products hereunder, [***]. 
 2.9
“Delivery Date” means the date on which delivery of Biotium Product(s) is specified in a Purchase Order that is accepted by Biotium. 

2.10 “DIAGNOSTICS” means government regulated products or processes for quantitative or qualitative testing of
samples of human or animal origin to produce results reported to clinicians intended to be used and/or used by such clinicians in the identification, staging, predisposition, diagnosis, prognosis, monitoring or treatment of disease or other
health-related conditions, including but not limited to the detection of pathogens, the detection of genetic disease or genetic pre-disposition to disease, and tissue transplantation typing. 

2.11 “Distributor” means a third party that resells Licensed Products to
End-Users under the LICENSEE name as set forth in Section 3.2 b), where such Licensed Products are resold as packaged and sold by LICENSEE thereunder, and subject to the use limitations of this Agreement.

 2.12 “End-User” means the ultimate user who purchases or otherwise
acquires Licensed Product(s) from LICENSEE or a Distributor as contemplated by this Agreement, whose use consumes or destroys the commercial utility of such Licensed Products, or after which use any remaining Licensed Product is discarded. 

2.13 “FIELD OF USE” means for RESEARCH and ASR purposes. The use of Licensed Products for providing medical or non-ASR human diagnostic testing is expressly excluded from the FIELD OF USE. 

  
 2 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT
IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 
  

 2.14 “Government Authority” means any governmental authority
or court, tribunal, agency, department, commission, arbitrator, board, bureau, or instrumentality of the United States of America or any other country or territory, or domestic or foreign state, prefecture, province, commonwealth, city, county,
municipality, territory, protectorate or possession, including, without limitation, any Agency. 
 2.15 “Intellectual
Property Rights” means Patents, inventions, discoveries, mask work rights, copyrights (including, without limitation, software, algorithms, computer programs, and multi-media works), trademarks, Confidential Information (as defined
herein), trade-secret, know-how, and any other intellectual property whether patentable or not. “Patents” shall mean U.S. and non-U.S.
(i) unexpired letters patent (including inventor’s certificates) that have not lapsed or been held invalid or unenforceable by a court or administrative body of competent jurisdiction from which no appeal can be taken or has been taken
within the required time period, including any substitution, extension, registration, confirmation, reissue, reexamination, renewal or any like filing thereof and (ii) pending applications for letters patent that have not been the subject of a
rejection notice from which an appeal cannot be taken or in respect of which the applicable period of appeal has expired, including any continuation, division or
continuation-in-part thereof and any provisional applications. 

2.16 “Invoice” means a BIOTIUM invoice issued to LICENSEE in accordance with the terms of this Agreement. 

2.17 “Laws” means all laws, statutes, ordinances, codes, regulations and other pronouncements having the effect
of law of any Government Authority. 
 2.18 “Licensed Product” means any commercial product of LICENSEE
incorporating Biotium Product, the use or sale of which would infringe (directly or indirectly) one or more Valid Claims within the BIOTIUM LICENSED PATENTS (each, a “Covering Claim” for such Licensed Product). 

2.19 “Licensed Service” means a service which is carried out using Licensed Products. 

2.20 “NET SALES” means the gross revenues received by LICENSEE and its Affiliates from the sale of Licensed
Product and/or Licensed Service to Third Parties less applicable Deductions. In the event that Licensed Product is sold or used in performing Licensed Service in the form of combination products or kits containing one or more other Active Components
other than the Licensed Product, NET SALES for such combination products, kits or Licensed Service will be calculated by multiplying the actual NET SALES of such combination products, kits or Licensed Service by the fraction A/B, where A is the
total number of Licensed Products in the combination product or kit and B is the total number of Active Components including the Licensed Product in the combination product or kit. For purposes of this Agreement, “Active
Components” shall mean components such as antibodies, antigens, fluorescent dyes, fluorescent proteins, beads and/or magnetic particles, and shall specifically exclude components such as buffers, packaging and media. 

2.21 “Party” means BIOTIUM or LICENSEE; “Parties” means BIOTIUM and LICENSEE. As used
in this Agreement, reference to “Third Parties” means persons or entities other than a Party or its Affiliates. 

2.22 “Purchase Order” means a LICENSEE purchase order issued to BIOTIUM in accordance with the terms of this
Agreement. 
 2.23 “Quarter” means one calendar quarter (a consecutive three-month period) of a Year. 

2.24 “Research” means the investigation of biological or biochemical processes or research and development of
biological or biochemical products. The term “Research” expressly includes, but is not limited to, the use of the Licensed Products in drug discovery or drug screening or other research to develop new products and services,
and to commercialize such new products and services. Uses which do not fall within this definition of the term “Research” are expressly excluded, including without limitation all diagnostic, vaccine, or therapeutic use. 

  
 3 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT
IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 
  

 2.25 “Specifications” means information specifying the
technical and performance criteria for Biotium Products that is set forth in Exhibit C. 
 2.26 “Territory”
means worldwide. 
 2.27 “Trademarks” means BIOTIUM’s trademarks, logos, and trade dress which may be
affixed either to the Licensed Products or on the packages/containers in which such Licensed Products are shipped, or which are included in written materials relating to or mentioning the Licensed Products, including the trademarks listed on Exhibit
D. 
 2.28 “Valid Claim” means any claim of (a) an issued and unexpired patent, which claim has not
lapsed or been revoked or held invalid, unpatentable or unenforceable by a court or administrative body of competent jurisdiction from which no appeal can be taken or has been taken within the required time period, and that has not been canceled,
withdrawn, abandoned, disclaimed, denied or admitted to be invalid or unenforceable, or (b) a pending patent application, which claim has not been canceled, withdrawn, abandoned, or the subject of a rejection notice from which an appeal cannot
be taken or in respect of which the applicable period of appeal has expired, and has been pending for less than [***] years from its earliest priority date. 

2.29 “Year” means calendar year. 

ARTICLE 3. SCOPE OF AGREEMENT 

3.1 This Agreement sets forth the terms and conditions that govern BIOTIUM’s supply of Biotium Products, as set forth in Exhibit
A, and LICENSEE’s right to resell and distribute Licensed Products under BIOTIUM LICENSED PATENTS. This Agreement does not apply to the purchase or supply of any other materials or services, and does not apply to the grant of any other rights,
other than as set forth herein. 
 3.2 Subject to all of the terms of this Agreement: 

(a) BIOTIUM hereby grants to LICENSEE and LICENSEE hereby accepts from BIOTIUM, a non-exclusive
license under BIOTIUM LICENSED PATENTS, without right to sublicense, for LICENSEE to make, have made, develop, have developed, use, have used, sell, have sold, offer to sell, have offered for sale, import, have imported, and otherwise commercialize
Licensed Products and perform and have performed Licensed Services in the FIELD OF USE in the Territory. Upon expiration of the last-to-expire Covering Claim for any Licensed Product and country, such license
for such Licensed Product and country will be fully-paid and royalty-free. 
 (b) The foregoing license includes the rights to
(i) convey to End-Users the right to use the Licensed Products in the FIELD OF USE, (ii) employ Affiliates to make, have made, developed, have developed, import, have imported, use, have used, sell,
have sold, and offer to sell, and have offered for sale Licensed Products and/or perform and have performed Licensed Services in the FIELD OF USE, (iii) employ Distributors, either directly or through Affiliates, to sell Licensed Products under
the label of LICENSEE to End-Users and convey to such End-Users the same rights conveyed under Subsection 3.2 b) (i) hereof, and (iv) convey to THIRD PARTIES
that purchase Licensed Products from LICENSEE, either directly or through AFFILIATES or Distributors, the right to re-sell Licensed Products under the label of such third party to End-Users to use the Licensed Product in the FIELD OF USE. Such a THIRD PARTY that purchases from the LICENSEE may re-sell Licensed Products through its own Distributors or
Affiliates. None of the foregoing shall be construed as a sub-license. 

  
 4 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT
IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 
  

 3.3 For purposes of clarification, LICENSEE, its Affiliates and its and their
customers shall have the right to use Licensed Products and LICENSED SERVICES in commercial research for the development of products and services, and shall be free to commercialize such products and services, but only to the extent that the
manufacture, use, sale or import of the products and services that result from such research would not otherwise infringe any Valid Claims under the BIOTIUM LICENSED PATENTS. 

3.4 No right or license is granted to LICENSEE under this Agreement to manufacture or have manufactured the Biotium Products. 

3.5 To the extent that the rights granted to LICENSEE are shared with one or more of its Affiliates pursuant to Section 3.2
hereunder, LICENSEE shall impose limitations and obligations so that such Affiliates shall be bound under the same limitations and obligations imposed on LICENSEE hereunder. 

ARTICLE 4. PRICE 

4.1 Exhibit A attached hereto sets forth the current U.S. list price for the Biotium Products (“Price”) which
prices shall remain fixed until at least the [***] anniversary of the Effective Date. Price may be increased upon the [***] anniversary date of the Effective Date to reflect increases to the costs of raw materials and other costs of manufacturing,
provided, however, that such increase shall not be greater than [***]. Biotium shall notify LICENSEE in writing at least [***] days in advance of any Price adjustment and shall provide reasonable documentation of the increase in costs of raw
materials or other costs of manufacturing that justify such Price increase. 
 4.2 Prices given in Exhibit A are exclusive of, and
LICENSEE shall be responsible for the payment of, shipping charges (including freight and insurance, customs fees, as well as any applicable sales, use, service, value added and similar taxes) on a carrier approved by LICENSEE. 

4.3 For the avoidance of doubt, BIOTIUM agrees to offer the same pricing for the Products as BIOTIUM is obligated to provide to
LICENSEE hereunder, to all Affiliates of LICENSEE, and LICENSEE Affiliates may issue Purchase Orders pursuant to this Agreement. 

ARTICLE 5. ORDERING 

5.1 Orders for the purchase of Products hereunder shall be submitted to BIOTIUM on a Purchase Order. All Purchase Orders must be
acknowledged by BIOTIUM and either accepted or rejected within [***] business days of receipt. In no event may BIOTIUM reject a Purchase Order unless such Purchase Order includes a requested Delivery Date that is not within the lead time for any
Product ordered thereunder specified in Exhibit A. All terms and conditions of sale or otherwise pertaining to the Products sold hereunder are set forth in this Agreement. The terms and conditions of this Agreement will control any and all
procurement of Product by or on behalf of LICENSEE and shall supersede the terms of any Purchase Orders, invoices, or other documents, including, without limitation, package inserts and labels, relating to the Product, issued by LICENSEE or BIOTIUM;
accordingly, such terms are null and void, unless agreed upon in writing by duly authorized representatives of both Parties. 
 5.2
Upon acceptance of a Purchase Order, BIOTIUM shall supply Products in accordance with the Specifications and ship such Products in accordance with the Delivery Date set forth in the Purchase Order. 

5.3 Purchase Orders will include the quantities and types of Products purchased by LICENSEE thereunder with Delivery Dates. LICENSEE
may cancel or defer any Purchase Order without penalty, provided that such cancellation notice is received by BIOTIUM at least [***] days prior to the scheduled delivery date for a Product shipment. If LICENSEE cancels or defers a Purchase Order
with less than the aforementioned notice BIOTIUM shall [***] minimize any charges to LICENSEE. 

  
 5 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT
IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 
  

 5.4 Products shall be packed and shipped in accordance with BIOTIUM’s standard
practices. LICENSEE may specify different shipping instructions, subject to agreement by BIOTIUM, provided that LICENSEE will be subject to an additional charge if the alternate method increases the cost of shipping, equal to the increased cost. All
packing shall conform to requirements of carrier’s tariffs. 
 ARTICLE 6. SHIPPING AND DELIVERY 

6.1 BIOTIUM shall deliver Products to LICENSEE no later than the Delivery Dates set forth in Purchase Orders accepted by BIOTIUM. Time
is of the essence. 
 6.2 All Products delivered pursuant to the terms of this Agreement shall be F.O.B. BIOTIUM manufacturing plant,
freight and insurance prepaid and added to the invoice, to LICENSEE’s address or other place of delivery as designated on the Purchase Order. LICENSEE may use LICENSEE’s designated carrier and insurer and in such case, LICENSEE shall
provide its account number for such carrier and BIOTIUM will use such account number for all shipments unless otherwise agreed to in writing. All customs, duties, costs, taxes, insurance premiums, and other expenses relating to such transportation
and delivery shall be at LICENSEE’s expense. 
 6.3 In the event circumstances of force majeure as defined in Section 21.2
exist which would prevent or delay delivery of Products by BIOTIUM, BIOTIUM shall have the right to apportion Products available for delivery among its various customers; provided that (a) BIOTIUM shall notify LICENSEE [***] upon becoming aware
of any anticipated prevention or delay of delivery and (b) BIOTIUM shall apportion Products [***] based on [***]. 
 6.4 Title,
as provided in this Agreement, and risk of loss with respect to all Products shall pass from BIOTIUM to LICENSEE upon transfer to the carrier, except for any Products that are rejected by LICENSEE. 

ARTICLE 7. SPECIFICATIONS AND QUALITY 

7.1 BIOTIUM shall manufacture and package and supply all Products in accordance with and to meet the Specifications. 

7.2 Biotium shall supply a Certificate of Analysis (C of A) for the Products with each shipment of such Products confirming and
certifying that the Products meet the Specifications. MSDS shall be readily available from Biotium upon request. If LICENSEE does not receive such C of A for any Product with the shipment thereof, such C of A shall be readily available from BIOTIUM
upon request. LICENSEE shall be responsible for distribution of information contained in the MSDS to its customers and employees, and if such information is legally required to accompany materials transferred by LICENSEE. 

BIOTIUM shall also provide LICENSEE with Agency certification, for those countries in which the applicable Agency is in the practice of
requiring any such certifications. 
 7.3 Although there may be parameters other than those set forth in this AGREEMENT that may
determine the suitability of the Biotium Products for incorporation into LICENSEE’s products and the use thereof in the FIELD OF USE, only the Specifications for the Biotium Products that are specifically set forth in this AGREEMENT, as may be
amended by written agreement of the Parties, shall be used to determine acceptance by LICENSEE of the Biotium Products with respect to incoming inspection under Article 8 below. 

  
 6 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT
IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 
  

 7.4 Process Changes. Notwithstanding anything herein to the contrary, BIOTIUM shall
not amend, change or supplement any of the following, except as may be required to comply with applicable Laws and regulations and Agency requirements, without LICENSEE’s prior written consent: (A) the Specifications; (B) the raw
materials used to manufacture the Products; or (C) the process for manufacturing the Products. Any change in any of the foregoing shall, in each case, comply with all applicable Laws, regulations and Agency requirements. BIOTIUM shall notify
LICENSEE in advance of making any such change that is required to comply with applicable Laws, regulations or Agency requirements and shall provide all information reasonably requested by LICENSEE related to any such change. In the event that
BIOTIUM desires to change any of the foregoing, BIOTIUM agrees to: (i) immediately notify LICENSEE of such change; and (ii) if LICENSEE agrees to such change, be responsible, at its expense, for ensuring that all Products manufactured
following such change conform to the Specifications and the Product quality and yields achieved during the validation batches. BIOTIUM shall continue to supply LICENSEE with Products approved under then current regulatory filings until such time as
the Products manufactured following such change are permitted under any new regulatory filings. If BIOTIUM makes any regulatory filings or otherwise attempts to obtain any Agency approvals, BIOTIUM must immediately notify LICENSEE whether such
changes have been approved or rejected. 
 7.5 Product Issues. BIOTIUM agrees to promptly notify LICENSEE of any lot failure,
manufacturing problems or similar issues that may impact LICENSEE’s ability to distribute Products or Licensed Products to its customers. Within [***] days following BIOTIUM’s receipt of any response or other notice from LICENSEE that a
problem has developed with a Product, BIOTIUM agrees to provide a detailed written response to LICENSEE outlining a plan to resolve the problem, to the extent such problem is related to BIOTIUM’s manufacture of the Product or obligations
hereunder. 
 7.6 Manufacturing Records. BIOTIUM agrees to retain all records relating to the manufacturing of Products for a period
of not less than [***] years, when applicable, from the date of manufacture of each batch of Product. BIOTIUM shall provide LICENSEE with complete and accurate copies of the appropriate documents for each production batch, upon LICENSEE’s
request. Upon written request to BIOTIUM, LICENSEE shall have the right to have representatives visit the manufacturing facilities of BIOTIUM during normal business hours to review BIOTIUM’s manufacturing operations, to assess its compliance
with ISO 9001 and applicable laws and regulations, and to discuss any related issues with BIOTIUM’s manufacturing and management personnel. 

ARTICLE 8. INSPECTIONS AND RETURNS 

8.1 Any return of the Products requires written authorization from BIOTIUM and a return authorization number. Any claim for shipping
discrepancies or damage must be made within [***] business days of receipt of the shipment. Errors due to improper packaging by BIOTIUM or failure to ship the correct Product in the correct quantities shall be resolved by BIOTIUM as requested by
LICENSEE, which may include return, replacement, reshipment, refund, etc., depending on the type and source of error; provided that in no event shall LICENSEE be obligated to pay for any Product it does not receive or for Product damaged as a result
of improper packaging. With respect to damage to Product caused during shipment the Parties will mutually work together to make any appropriate claims with the applicable carrier and insurer. Any credit for return of the Products ordered in error
may be subject to a nominal restocking fee. BIOTIUM shall be responsible for shipping costs for all Product returned as a result of BIOTIUM’s error. 

8.2 LICENSEE shall notify BIOTIUM of any claim of a non-conforming Product within [***]
business days after LICENSEE receives such Products from BIOTIUM or [***] days from when LICENSEE becomes aware of the non-conformance, whichever is later. The absence of any such notice within such period
shall constitute acceptance of the Products by LICENSEE, but does not constitute a waiver of any rights of LICENSEE or obligations of BIOTIUM with respect to Products hereunder. Within [***] business days after LICENSEE provides any such notice,
LICENSEE shall receive notification whether BIOTIUM believes such Products were non-conforming when shipped. If such notification confirms, or the Third Party laboratory described below determines, that the
Products were non-conforming when shipped or if BIOTIUM fails to provide any notice within such [***] business day period, BIOTIUM will replace such Products within [***] days and reimburse LICENSEE for all
costs and expenses incurred in connection with the replacement. If such timely notification denies that such Products were non-conforming when shipped, BIOTIUM and LICENSEE shall use their reasonable
commercial efforts to establish the cause of the discrepancy, and to resolve the matter. If the Parties are unable to resolve the matter, then they shall submit a sample of the applicable Product to a mutually acceptable independent Third Party
laboratory for testing, whose determination will be final and binding on the Parties. The Party against whom the laboratory rules will bear the costs of the testing. LICENSEE shall arrange the disposal and destruction of any non-conforming Product at BIOTIUM’s expense, or at BIOTIUM’s request and expense, LICENSEE shall return the non-conforming Product to BIOTIUM. 

  
 7 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT
IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 
  

 8.3 BIOTIUM shall not be responsible for any
non-conformance that is due to any failure by the carrier or LICENSEE to handle or store the Products as indicated on the label, Specifications, or accompanying product information. 

ARTICLE 9. TECHNICAL SUPPORT 

9.1 BIOTIUM shall provide to LICENSEE scientific and technical information regarding the use of the Products, subject to provisions of
Section 15.1 of this Agreement, available to BIOTIUM and useful to obtain registrations, licenses, and permits useful for the sale and distribution of the Products, or to respond to inquiries from customers, or governmental or regulatory
authorities. Unless otherwise agreed to in writing by the Parties, no additional consideration is required for the transfer of technical information to LICENSEE, and LICENSEE and its Affiliates assume sole responsibility for results obtained in
reliance thereon, unless resulting from the negligence or willful misconduct of BIOTIUM or its employees or agents. 
 ARTICLE 10. PAYMENT

 10.1 Upon or after delivery of the Product to the F.O.B. point, BIOTIUM shall submit an Invoice to LICENSEE that specifies the
Purchase Order number, Product(s) delivered, quantity and unit price of each Product delivered, and shipping date. LICENSEE agrees to pay the undisputed amount of all Invoices submitted by BIOTIUM within [***] days from LICENSEE’s acceptance of
the Products subject to the Invoice. The due date for disputed amounts shall occur [***] days after the dispute is resolved and a confirmed Invoice is received by LICENSEE. 

10.2 Unless otherwise mutually agreed in writing, all payments to BIOTIUM shall be made by i) check drawn on a bank in the United
States; ii) direct deposit through a bank specified by the applicable recipient; or iii) wire transfer. 
 10.3 All amounts payable
under this Agreement to BIOTIUM shall be in the currency of the United States of America. LICENSEE shall be responsible for any bank transfer fees, which may not be credited against or withheld from the amount due to BIOTIUM. 

10.4 If payment is not received by the due date, an interest charge may be added at the rate of [***] per month ([***] per year) or the
maximum legal rate, whichever is less, to unpaid invoices from the due date thereof. Where invoices are not timely paid and not subject to a bona fide dispute between the Parties, subsequent shipments may be delayed or subject to prepayment until
overdue amounts are paid. 
 10.5 Commencing at the end of [***] following the Effective Date of this Agreement and within [***] days
following the end of [***] during the term of this Agreement, LICENSEE shall furnish BIOTIUM with a written report showing in reasonable detail its NET SALES for each Licensed Product sold or otherwise transferred for value, during [***] and
accounting for amounts payable hereunder pursuant to Article 12 (proprietary rights) and Exhibit B (fees and royalties). If no sales of Licensed Products have been made during [***] after the first commercial sale of Licensed Products, then a
statement to this effect is required. Such report shall include at least the following: 
 (a) separately itemized quantities of
Licensed Products sold during such [***]; 
 (b) the aggregate NET SALES of each Licensed Product; 

  
 8 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT
IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 
  

 (c) the calculation of net royalties based on a royalty rate as defined in Exhibit B;

 (d) the net royalties due. 

Such report shall be sent to BIOTIUM as set forth in Section 19.1 (notice requirements), which shall be accompanied by remittance of any
and all royalties due for such [***]. 
 10.6 For sales of Licensed Products invoiced in United States dollars, NET SALES and
royalties payable shall be expressed in United States dollars. For sales outside the United States, the exchange rate used to compute NET SALES shall be the exchange rate used in LICENSEE’s accounting system. 

10.7 Notwithstanding the provisions of Section 21.2 (Force Majeure), if at any time legal restrictions prevent prompt payment of
part or all royalties owed to BIOTIUM by LICENSEE with respect to any country where a Licensed Product is sold or distributed, LICENSEE shall have the right, in its sole discretion, to make such payments by depositing the amount thereof in local
currency to BIOTIUM’s account in a bank or other depository BIOTIUM may request in such country. If the royalty rate specified in the Agreement should exceed the permissible rate established in any country, the royalty rate for sales in such
country shall be adjusted to the highest legally permissible or government-approved rate. 
 10.8 If any Valid Claim included within
the BIOTIUM LICENSED PATENTS that is a Covering Claim for any Licensed Product or country is held invalid in a final decision by a court of competent jurisdiction from which no appeal has or can be taken, or if any such Covering Claim expires, is
allowed to lapse, or is revoked, or is otherwise no longer a Valid Claim, then all obligations to pay royalties on sales of such Licensed Product in such country based on such Valid Claim or any claim patentably indistinct therefrom will cease as of
the date of such final decision, expiration, lapse, revocation or otherwise. LICENSEE will not, however, be relieved from paying any royalties that accrued before such date or that are based on another Covering Claim that remains a Valid Claim. 

10.9 LICENSEE shall keep books of account in sufficient detail, in accordance with generally accepted accounting principles, to comply
with the requirements of Section 10.5 (royalty reporting) and other terms of this Agreement. Commencing upon the [***] of the Effective Date of this Agreement (and each [***] thereafter) and up to [***] calendar days thereafter (defined herein
after as the “[[***] Period”), upon the written request of BIOTIUM, LICENSEE shall permit, upon reasonable written notice, an independent certified public accountant, selected by BIOTIUM and acceptable to LICENSEE, to inspect
those books of account, during normal business hours to verify the accuracy of any royalty report provided under Section 10.5, but no more often than [***]. For clarity, LICENSEE shall provide access to its own records, which includes worldwide
total sales, but shall not be required to provide access to the records of its foreign AFFILIATES for any individual country where sales in that country account for less than [***] of total sales of identified Licensed Products. The accounting firm
shall disclose to BIOTIUM only whether the royalty reports are correct or not and the specific details concerning any discrepancies. No other information shall be shared. To facilitate such record keeping, LICENSEE shall ensure that all Licensed
Products sold by LICENSEE or its AFFILIATES shall bear a serial or lot number. BIOTIUM agrees that accounting information disclosed to the independent certified public accountant during such inspection shall be treated as LICENSEE’s
Confidential Information. In the event BIOTIUM exercises the right to have an independent certified public accountant inspect LICENSEE’s records, the inspection must be completed within [***] calendar days from the [***] Period. The expense of
such inspection shall be borne by BIOTIUM unless the inspection indicates that LICENSEE has reported and paid less than [***] of the full amount of royalties due and owing to BIOTIUM for the period covered by such inspection, in which case the
reasonable expenses shall be borne by LICENSEE, in addition to payment of the underpayment and interest that may be due. BIOTIUM shall pay to LICENSEE the amount of any overpayment disclosed in such inspection. 

  
 9 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT
IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 
  

 ARTICLE 11. RESALE RESTRICTIONS 

11.1 It is the intention of the Parties that this Agreement represents a value added business relationship. Except as expressly
authorized in this Agreement, LICENSEE shall not i) decompile or disassemble or otherwise attempt to reverse engineer any portion or components of the Biotium Products or otherwise attempt to derive or obtain any structure, process, technique,
technology, know-how or ideas underlying or contained in the Biotium Products, ii) alter, modify or derivatize any portion or components of the Biotium Products, iii) authorize, or assist any Third-Party to do
any of the foregoing. BIOTIUM agrees that LICENSEE shall have the right to conjugate the Biotium Products to antibodies. 
 ARTICLE 12.
PROPRIETARY RIGHTS 
 12.1 Multiple proprietary rights of BIOTIUM, some of which are identified in Exhibit D, are the basis of
the licenses granted under this Agreement. For the convenience of the Parties, consideration for all licenses granted under this AGREEMENT are consolidated into LICENSEE’s purchase price of the Licensed Products and a consolidated set of
royalty and license payments by LICENSEE as set forth in Exhibit B (fees and royalties). 
 12.2 As set forth in Sections 3.2 a) and
b), the transfer of Licensed Products to End-Users, as authorized hereunder, is accompanied by a label license for such End-Users to use the Licensed Products in the
FIELD OF USE. LICENSEE shall mark all Licensed Products or its accompanying product inserts, as determined by LICENSEE, with the label license that is set forth in Exhibit E (label license). In the event LICENSEE desires to commercialize a Licensed
Product in the field of DIAGNOSTICS, LICENSEE shall pay the license issuance fee for DIAGNOSTICS as agreed by the Parties upon signing an addendum to this AGREEMENT. 

12.3 Consistent with the grant and limitations in Article 3 (Scope of Agreement), LICENSEE shall [***] actively promote the sale of
Licensed Products. LICENSEE understands, however, that there may be proprietary rights owned by Third Parties that may be necessary for the commercialization of Licensed Products, and LICENSEE or its End-Users
agrees that i) securing access to such Third Party rights is the responsibility of LICENSEE or its End-Users, and ii) subject to the following sentence and Sections 12.5 and 14.3 and Article 17, neither
BIOTIUM nor any Affiliate of BIOTIUM has any responsibility or liability with respect to any such Third Party proprietary rights. BIOTIUM represents that to its knowledge no Third Party proprietary rights are required for LICENSEE to exercise its
rights under this Agreement. 
 12.4 LICENSEE shall [***] notify BIOTIUM in writing of any claim received by LICENSEE in writing that
any Biotium Product incorporated into a Licensed Product, or any Trademark licensed hereunder for use by LICENSEE in conjunction with any Licensed Product, infringes any copyright, trademark, patent or similar proprietary right of any party, or
misappropriates any trade secret or similar proprietary right of any party. 
 12.5 BIOTIUM does not warrant the validity or
enforceability of any Intellectual Property Rights relating to any Products. BIOTIUM warrants and represents, however, that at the time of the sale it is not aware of any infringement of any patents or patent applications or other Intellectual
Property Rights owned by Third Parties which would prevent LICENSEE from using the Products. 
 ARTICLE 13. TRADEMARKS, PROMOTIONAL
MATERIALS 
 13.1 Subject to the terms of this Agreement, BIOTIUM hereby grants to LICENSEE a
non-transferable, nonsublicensable, nonexclusive limited license within the Territory to use the Trademarks, including CF®, without modification unless
approved by BIOTIUM, solely in connection with LICENSEE’s marketing, sale and distribution of the Licensed Products. 

  
 10 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT
IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 
  

 13.2 Licensed Product shall bear BIOTIUM’s CF® trademark for all product literature, including, but not limited to, product manual, MSDS and web product description. LICENSEE, its Affiliates, their distributors shall use or maintain the CF® trademark on Licensed Product sold, LICENSEE shall only advertise, promote, and market within the Territory the Licensed Products that bear BIOTIUM’s CF® trademark. All other labeling of Licensed Products shall be at the discretion of LICENSEE and its Affiliates. Notwithstanding anything to the contrary herein, LICENSEE shall have the right to
sell Licensed Products under LICENSEE’s own trademark, including as shown in the materials specification sheet attached hereto as Exhibit F or any similar documentation. BIOTIUM reserves the right to modify Trademarks or substitute alternative
marks upon the written consent of LICENSEE (not to be unreasonably withheld) for any or all of the Trademarks at any time upon [***] days prior written notice to LICENSEE and this Agreement including Exhibit D shall upon LICENSEE’s written
consent automatically be amended to reflect such change. LICENSEE will use commercially reasonable efforts to incorporate such approved alternative Trademarks as soon as practical under the circumstances. The rights to the Trademarks granted under
this Article shall automatically terminate upon the sale or other disposition to an End-User of the last Product sold to LICENSEE hereunder. Except as set forth in this Agreement, nothing contained in this
Agreement shall grant to LICENSEE any right, title or interest in the Trademarks, whether or not specifically recognized or perfected under applicable laws, and LICENSEE irrevocably assigns to BIOTIUM all such right, title, and interest, if any, in
any Trademarks. At no time during the term of this Agreement shall LICENSEE challenge or knowingly assist others to challenge the Trademarks or the registration thereto. 

13.3 All representations of BIOTIUM Trademark(s) that LICENSEE intends to use shall be exact copies of those used by BIOTIUM or shall
first be submitted to Biotium for approval (which shall not be unreasonably withheld) of design, color and other details. LICENSEE shall not engage in any activity intended to adversely affect the name, reputation or goodwill of BIOTIUM or the
Products. In addition, LICENSEE shall fully comply with all reasonable guidelines, if any, communicated by BIOTIUM concerning the use of BIOTIUM Trademark(s). 

13.4 BIOTIUM promotional and technical materials and publications, including electronic versions of such materials and publications
displayed on the Web site of BIOTIUM or its Affiliates, are protected by copyright. With regard to such works that originate with BIOTIUM or its Affiliates (i.e., they are not attributable to a Third Party), BIOTIUM hereby grants LICENSEE the right
to display, copy, and make derivative works of such materials and/or publications in whole or in part, as they relate to the Products. BIOTIUM will provide at no cost to LICENSEE electronic copies of art work related to the Products for use in
LICENSEE’s marketing materials. 
 13.5 LICENSEE shall notify BIOTIUM of any infringement or misuse of BIOTIUM’s Trademarks
of which LICENSEE becomes aware. BIOTIUM shall be solely responsible for prosecution and enforcement of any infringement of the BIOTIUM Trademarks. 

ARTICLE 14. REPRESENTATIONS AND WARRANTIES 

14.1 BIOTIUM represents and warrants to LICENSEE that it has the lawful right to grant to LICENSEE the license provided for in this
Agreement. 
 14.2 Each Party represents and warrants to the other that (i) it is a company or corporation duly organized,
validly existing and in good standing under the laws of the jurisdiction in which it is organized; and (ii) this Agreement constitutes the legal, valid and binding obligation of such Party, enforceable against such Party in accordance with its
terms. 
 14.3 BIOTIUM represents and warrants that i) the Biotium Products transferred to LICENSEE pursuant to this Agreement shall
be delivered with full title, free and clear of all liens, claims and encumbrances, and will not be articles that may not be introduced into interstate commence in accordance with applicable Laws, ii) that the Biotium Products conform at the time of
delivery and will conform to the Specifications for a period of [***] from delivery by BIOTIUM, provided that the Biotium Products are handled by LICENSEE under conditions as recommended in BIOTIUM’s product information sheet, and shall be
merchantable and free of all defect in material and workmanship, iii) the Biotium Products when sold to LICENSEE, will not infringe the Intellectual property rights of any Third Party and iv) the BIOTIUM Trademarks licensed hereunder do and will not
infringe any trademark or other Intellectual Property Right of any Third Party. 

  
 11 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT
IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 
  

 14.4 If, after LICENSEE’s acceptance of Biotium Products under Section 8.2,
BIOTIUM receives notice of defects or nonconformance to the Specifications during the warranty period, BIOTIUM will replace the affected Products at no cost to LICENSEE. If BIOTIUM is unable, within [***] days, to replace or correct a defect or non-conformance in a Biotium Product to a condition as warranted, LICENSEE will be entitled to a refund of the purchase price. BIOTIUM may request return of the defected or
non-conforming Biotium Product. BIOTIUM will pay expenses for shipment of both defective and replacement Products. 

14.5 The above warranties do not apply to defects resulting from improper or inadequate handling and storage by LICENSEE or its End-Users or Distributors; unauthorized modification; improper use or operation outside of the Specifications for the Biotium Product; and abuse, negligence, accident, loss or damage in transit. 

14.6 All Product defects or suspected defects during the warranty period will be managed by an authorized LICENSEE representative who
may place a call to BIOTIUM’s designated technical service followed up with the description of the Product problem in sufficient detail as to allow BIOTIUM to assess the source of the problem. All service calls placed by LICENSEE will be
responded to either by email or by phone within [***] business days with a proposed remedy to the Product’s problem being determined by BIOTIUM as soon as commercially feasible after LICENSEE’s initial service call. 

14.7 BIOTIUM represents, warrants and covenants that: (i) all Products shall, at the time of delivery, have been manufactured,
stored and packaged in accordance with all applicable Laws, regulations and Agency requirements; and (ii) BIOTIUM shall comply with, and give all notices required by, all applicable Laws, ordinances, rules, regulations and Lawful orders of any
public authority or Agency (including, without limitation, child labor Laws) bearing on the performance of this Agreement. BIOTIUM shall notify LICENSEE if it becomes aware of any non-compliance with the
foregoing requirements and shall take all appropriate action necessary to comply with such Laws, ordinances, rules, regulations and Lawful orders. 

14.8 There is no actual or, to BIOTIUM’s knowledge, threatened litigation concerning: (i) BIOTIUM that affects BIOTIUM’s
ability to comply with this Agreement; or (ii) any Products. 
 14.9 These representations and warranties shall be ongoing
representations and warranties during the term of this Agreement, and BIOTIUM shall immediately notify LICENSEE of any change in the status of the representations and warranties set forth in this Article 14. Any breach of this Article 14 shall
constitute a material breach of the Agreement. 
 14.10 EXCEPT FOR THE EXPRESS WARRANTIES AND REPRESENTATIONS STATED IN THIS
AGREEMENT, NEITHER PARTY NOR ITS AFFILIATES MAKES ANY ADDITIONAL WARRANTIES OR REPRESENTATIONS, EXPRESS OR IMPLIED OR STATUTORY, AS TO ANY MATTER WHATSOEVER AND BIOTIUM AND ITS AFFILIATES EXPRESSLY DISCLAIM ANY AND ALL WARRANTIES OF MERCHANTABILITY
OR FITNESS FOR A PARTICULAR PURPOSE. 
 ARTICLE 15. CONFIDENTIALITY 

15.1 Each Party agrees to maintain, and require its Affiliates and its and their employees to maintain, Confidential Information of the
other Party with the same degree of care it uses to protect its own Confidential Information, but in no event less than a reasonable degree of care. Each Party agrees not to use, and require its Affiliates and its and their employees not to use, the
Confidential Information of the other Party for any purpose other than performing its obligations and exercising its rights under this Agreement, except as otherwise explicitly set forth in this Article. 

  
 12 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT
IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 
  

 15.2 Each Party agrees to maintain in confidence and not to disclose to any third
party, both during and for [***] years subsequent to the term of this Agreement, any Confidential Information of the other Party or its Affiliates hereunder. The above notwithstanding, royalty reports shall remain confidential in perpetuity. 

15.3 Notwithstanding anything in this Agreement to the contrary, BIOTIUM and LICENSEE may disclose Confidential Information on a need-to-know basis to their respective Affiliates, and their respective employees, agents, consultants, and contractors, provided that any such parties are bound by a
substantially similar duty of confidentiality and non-use as this Article 15. 
 15.4 Without
granting any right or license to the use of its Confidential Information, except as specifically provided hereunder, each Party agrees that the limitations of non-use and
non-disclosure of Confidential Information it provides to the other Party under this Agreement shall not apply to such information, to the extent and only to the extent, that the receiving Party can establish
by competent evidence that it: 
 (i) is now or hereafter becomes generally known or available to the public without the receiving
Party’s breach of this Agreement or any confidentiality agreement between the Parties; or 
 (ii) is independently developed by
or for the receiving Party by individuals without access to or knowledge of the Confidential Information of the providing Party; or 

(iii) was acquired by the receiving Party before receiving such information from the providing Party under this Agreement, without an
obligation of confidentiality owed to the disclosing party with respect to such information; or 
 (iv) is hereafter rightfully
furnished to the receiving Party by a third party without any breach of an obligation of confidentiality to the providing Party. 

15.5 For purposes of clarifying Section 15.4 (confidentiality exclusions), information that is combined, synthesized or used by
the providing Party in a particular manner, as provided to the receiving Party under this Agreement, shall not be deemed “known”, “available”, “developed”,
“acquired”, or “furnished” separately to the receiving Party merely because the various pieces of information were previously known, available, developed, acquired, or furnished without being so
combined, synthesized or used. 
 15.6 A receiving Party may disclose Confidential Information if required to do so by applicable
law, an administrative or court order, or governmental regulation (including regulations applicable to the public sale of securities); provided that the receiving Party promptly notifies, if possible, the providing Party when it learns that
disclosure may be required, to enable the disclosing Party to seek a protective order for the disclosure of the Confidential Information. Any information disclosed pursuant to this Section 15.6 will remain the Confidential Information of the
providing Party and subject to this Agreement. 
 15.7 A Party may, without the prior written consent of the other Party, disclose
the terms of this Agreement to (a) its Affiliates, or their lawyers or other paid consultants or advisors, under substantially the same terms as this Article 15 (confidentiality requirements), solely for the purpose of discussions related to
this Agreement and (b) actual and bona fide potential investors, acquirors, lenders and other business partners, on a need-to-know basis and under customary
confidentiality obligations. Any information disclosed pursuant to this Section 15.7 will remain the Confidential Information of the providing Party and subject to this Agreement. A Party may also disclose the terms of this Agreement to the
extent required under applicable Laws (including regulations applicable to the public sale of securities), provided that such Party seeks confidential treatment of the sensitive technical, financial and commercial terms of this Agreement, to the
extent permitted under applicable Laws, and gives the other Party advance notice of such disclosure. 

  
 13 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT
IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 
  

 15.8 Any announcements or similar publicity with respect to the execution of this
Agreement shall be agreed upon among the Parties in writing in advance of such announcement. Neither Party shall make a public announcement related to this Agreement without the prior written consent of the other Party, except that information
previously approved for disclosure under this Section 15.8 may be publicly disclosed without such consent. Notwithstanding the foregoing, each Party may disclose information to the extent required by Law (including regulations applicable to the
public sale of securities) without the other Party’s consent, and shall give advance notice to the other Party of such disclosure. 

15.9 The price of Biotium Products granted to LICENSEE pursuant to this Agreement is Confidential Information of the Parties, and
neither Party shall disclose such price in any quote to any third party, except for disclosures otherwise permitted in this Article 15. 

15.10 No chemical structures, components or formulations of BIOTIUM Products shall be disclosed by LICENSEE without written permission
from BIOTIUM, unless such information is publicly identified by BIOTIUM in conjunction with BIOTIUM Products or is required to be disclosed by applicable Laws. 

15.11 Upon termination of this Agreement, the Parties will destroy or return to the disclosing party Confidential Information received
from the other in its possession within [***] days following the receipt of a written notice requesting such destruction or return. The Parties will provide each other, within [***] days following such destruction or return, with a written notice
that Confidential Information has been returned or destroyed. Each Party may, however, retain one copy of Confidential Information for archival purposes in secure files. 

ARTICLE 16. LIMITATION OF LIABILITY 

16.1 NOTWITHSTANDING ANYTHING CONTAINED IN THIS AGREEMENT TO THE CONTRARY (BUT SUBJECT TO SECTION 16.3), IN NO EVENT SHALL EITHER PARTY
BE LIABLE, WHETHER IN CONTRACT, TORT, WARRANTY, OR UNDER ANY STATUTE (INCLUDING WITHOUT LIMITATION ANY TRADE PRACTICE, UNFAIR COMPETITION OR OTHER STATUTE OF SIMILAR IMPORT) OR ON ANY OTHER BASIS, FOR INDIRECT, PUNITIVE, MULTIPLE, INCIDENTAL,
CONSEQUENTIAL OR SPECIAL DAMAGES SUSTAINED BY A PARTY OR ANY OTHER PERSON ARISING OUT OF OR IN CONNECTION WITH ANY ASPECT OF THIS AGREEMENT OR ITS PERFORMANCE OR ANY FAILURE IN PERFORMANCE OR BREACH, OR THE USE OR PERFORMANCE, OR CONSEQUENCES OF USE
OR PERFORMANCE, OF ANY PRODUCTS MANUFACTURED OR FURNISHED BY BIOTIUM OR LICENSEE WHETHER OR NOT FORESEEABLE AND WHETHER OR NOT A PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGE, INCLUDING, WITHOUT LIMITATION, DAMAGES ARISING FROM OR RELATED TO
LOSS OF USE, LOSS OF DATA, FAILURE OR INTERRUPTION OR FOR LOSS OF REVENUE OR PROFITS, LOSS OF GOODWILL, OR LOSS OF BUSINESS UNLESS EXPLICITLY PROVIDED FOR HEREIN. 

16.2 TO THE EXTENT PERMITTED BY APPLICABLE LAW, THE TOTAL AGGREGATE LIABILITY OF EITHER PARTY ARISING FROM THIS AGREEMENT SHALL IN NO
EVENT EXCEED [***]. 
 16.3 NOTWITHSTANDING THE FOREGOING, SECTIONS 16.1 AND 16.2 WILL NOT APPLY TO DAMAGES AVAILABLE FOR GROSS
NEGLIGENCE, WILLFUL MISCONDUCT OR BREACH OF ARTICLE 15 OR INDEMNIFICATION OBLIGATIONS UNDER ARTICLE 17. 

  
 14 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT
IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 
  

 16.4 IT IS EXPRESSLY UNDERSTOOD AND AGREED THAT EACH AND EVERY PROVISION OF THIS
AGREEMENT WHICH PROVIDES FOR A LIMITATION OF LIABILITY, DISCLAIMER OF WARRANTIES OR EXCLUSION OF DAMAGES, IS INTENDED BY THE PARTIES TO BE SEVERABLE AND INDEPENDENT OF ANY OTHER PROVISION AND TO BE ENFORCED AS SUCH. 

16.5 LICENSEE shall maintain in effect product liability insurance, in an amount of at least one million dollars. 

ARTICLE 17. INDEMNIFICATION 

17.1 LICENSEE agrees to defend the BIOTIUM Indemnified Parties at its cost and expense, and will indemnify and hold BIOTIUM, its
Affiliates and their respective directors, officers, employees and agents (the “BIOTIUM Indemnified Parties”) harmless from and against any liabilities, losses, costs, damages, fees or expenses (including reasonable
attorney’s fees) arising out of any claim brought by a Third Party to the extent resulting from (i) any breach by LICENSEE of any of its representations, warranties or obligations pursuant to this Agreement or (ii) personal injury or
property damage from the use, sale or other disposition of any product or service offered by LICENSEE and/or collaborators under this Agreement to the extent such injury or damage is caused by LICENSEE’s failure to handle or use the Licensed
Products as instructed or use by LICENSEE of the Licensed Product outside the scope of the license, rights, and permissions granted or authorized under this Agreement, except in all cases to the extent caused by the negligence or willful misconduct
of any BIOTIUM Indemnified Parties or BIOTIUM’s breach of this Agreement. 
 17.2 BIOTIUM agrees to defend the LICENSEE
Indemnified Parties at its cost and expense, and will indemnify and hold LICENSEE, its Affiliates, their Distributors, their customers, and their respective directors, officers, employees and agents (the “LICENSEE Indemnified
Parties”) harmless from and against any liabilities, losses, costs, damages, fees or expenses (including reasonable attorney’s fees) arising out of any claim brought by a Third Party to the extent resulting from (i) any breach
by BIOTIUM of any of its representations, warranties or obligations pursuant to this Agreement or (ii) personal injury or property damage arising from or related to Biotium Product provided under this Agreement other than to the extent such
injury or damage is caused by LICENSEE’s failure to handle or use the Products as instructed by BIOTIUM or a use by LICENSEE of the Product outside the scope of the license, rights, and permissions granted or authorized under this Agreement, or
(iii) the negligence or willful misconduct of any BIOTIUM Indemnitee, except in all cases to the extent caused by the negligence or willful misconduct of any LICENSEE Indemnified Parties or LICENSEE’s breach of this Agreement. 

BIOTIUM agrees to defend, indemnify and hold harmless the LICENSEE Indemnified Parties from and against any liabilities, losses, costs,
damages, fees or expenses (including reasonable attorney’s fees) arising out of any claim brought by a Third Party alleging that the Product infringes any Intellectual Property Right of a Third Party except where such infringement (i) is
due to a combination with, an addition to, or a modification of the Product after delivery by BIOTIUM hereunder wherein the Product itself would not infringe but for such combination, addition to, or modification, or (ii) is due to a use of the
Product not authorized by this Agreement. 
 BIOTIUM agrees to defend, indemnify and hold harmless the LICENSEE Indemnified Parties from and
against any liabilities, losses, costs, damages, fees or expenses (including reasonable attorney’s fees) arising out of compliance with the label licensing requirements of this Agreement including, without limitation, the label licensing
requirements of Section 12.2 and trademark labeling requirements of Article 13. 

  
 15 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT
IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 
  

 17.3 Whenever any claim shall arise for indemnification hereunder, the Party seeking
indemnification (the “Indemnified Party”) shall promptly notify the Party from whom indemnification is sought (the “Indemnifying Party”). Such notice shall specify the nature of the claim and, when
known, the facts constituting the basis for, as well as the amount or an estimate of the amount of the liability arising from, such claim. Failure to promptly notify shall not relieve a Party from its indemnity obligations hereunder except to the
extent of prejudice caused by such failure. The Indemnified Party shall not settle or compromise any claim by a Third Party for which it is entitled to indemnification hereunder without the prior written consent of the Indemnifying Party, which
shall not be unreasonably withheld, unless suit shall have been instituted against it and the Indemnifying Party shall not have taken control of such suit after notification thereof as provided in Section 17.4. 

17.4 In connection with any claim giving rise to indemnity under Article 17 of this Agreement, the Indemnifying Party at its sole cost
and expense shall assume the defense of any such claim or legal proceeding. The Indemnified Party shall be entitled to participate in (but not control) the defense of any such action, with its counsel and at its own expense. If the Indemnifying
Party does not assume the defense of any such claim or litigation resulting therefrom within [***] after the date written notice of such claim is given, the Indemnified Party may defend against such claim or litigation, without prejudice to pursue
its rights of indemnity under this Agreement. In such event, the Indemnified Party may defend in a manner as it may deem appropriate, including, but not limited to, settling such claim or litigation on such terms as the Indemnified Party may deem
appropriate, and the Indemnifying Party shall be entitled to participate in (but not control) the defense of such action, with its counsel and at its own expense. The Parties shall cooperate with each other in the defense of any such Third Party
claim pursuant to this Article 17. 
 ARTICLE 18. TERM AND TERMINATION 

18.1 This Agreement shall commence on the Effective Date and, unless terminated earlier pursuant to this Article, this Agreement shall
expire on the expiration of the last to expire of the Valid Claims within the BIOTIUM LICENSED PATENTS. 
 18.2 In the event that no
purchases of the Biotium Products are made for a [***] period, either Party may, at its election, terminate this Agreement upon [***] days prior written notification to the other according to Section 19.1 (notice requirements); provided that,
if such termination is by BIOTIUM, LICENSEE may cure such lack of purchases during such [***] day period after notice is received by purchasing Product. 

18.3 This Agreement shall terminate upon written notice by one Party to the other in the event the other Party shall become insolvent,
or shall ask its creditors for a moratorium, or shall file a voluntary bankruptcy petition, or shall suffer appointment of a temporary or permanent receiver, trustee, or custodian, for all or a substantial part of its assets who shall not be
discharged within [***] days. 
 18.4 Either Party may terminate this Agreement for material breach by the other Party of this
Agreement by notifying the other Party in writing of such breach and allowing the other Party [***] days within which to cure such breach. If such breach is not cured within [***] days from receipt of such notice of breach, the non-breaching Party may terminate this Agreement by written notice to the breaching Party; provided that (a) if such breach is capable of cure but not during such
[***]-day period, then the non-breaching Party shall not have the right to terminate this Agreement if the breaching Party commences diligent efforts to cure such breach
within such period and for so long as such efforts continue and (b) if the breaching Party disputes in good faith the existence or materiality of a breach described in any such notice, the non-breaching
Party shall not have the right to terminate this Agreement unless and until there is a final determination in accordance with Section 21.5 that the other Party has materially breached this Agreement and such other Party fails to cure such
breach within [***] days thereafter. 
 18.5 Expiration or termination of this Agreement for any reason shall not release any Party
hereto from any liability which, at the time of such expiration or termination, has already accrued to the benefit of the other Party or which is attributable to a period prior to such expiration or termination nor preclude any Party from pursuing
any rights and remedies it may have hereunder or at law or in equity with respect to any breach of this Agreement. In particular, LICENSEE’s payment obligations accrued through termination as well as obligation of both Parties under firm orders
for purchase and delivery of Products at the time of such termination shall survive any termination of this Agreement. 

  
 16 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT
IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 
  

 18.6 Any termination of this Agreement shall not affect the rights and obligations set
forth in the following Sections and Articles: Section 5.1 (with respect to Purchase Orders submitted during the term of this Agreement), 7.6 and 18.6 and Articles 2, 3 (with respect to Products purchased during the term of this Agreement), 5.1,
8, 9, 10, 14, 15, 16, 17, 19, 20, and 21, any terms that by their nature should survive, and this paragraph shall survive the expiration or termination of this Agreement for any reasons. 

ARTICLE 19. NOTICES 

19.1 All notices and requests required or authorized hereunder shall be given in writing either by personal delivery; by registered or
certified mail, return receipt requested; or by recognized overnight courier. Such notice shall be deemed to have been given upon such date that it is so personally delivered; the date three (3) days after it is deposited in the mail; or the
date the same is received if sent by overnight courier, irrespective of the date appearing therein. 
  

					
		 	If to BIOTIUM:	  	BIOTIUM, INC.
	 	 	 	  	Attention: Business Development
	 	 	 	  	46117 Landing Parkway
	 	 	 	  	Fremont, CA 94538
			
		 	If to LICENSEE:	  	Cytek Biosciences, Inc. Attention:
	 	 	 	  	46107 Landing Parkway
	 	 	 	  	Fremont, CA 94538

 ARTICLE 20. DISPUTE RESOLUTION 

20.1 In the event any Party claims breach of this Agreement, or in the event of any other dispute arising out of or in connection with
this Agreement, the Parties shall consult with each other in good faith on the most effective means to cure the breach and to achieve any necessary restitution of its consequences or resolve the dispute. This consultation shall be undertaken within
a period of [***] days following the receipt of a written request to consult, and the consultation period shall not exceed [***] days. Each Party shall have the right to seek injunctive or other equitable relief from a court of competent
jurisdiction, and such an action may be filed and maintained notwithstanding any ongoing consultation between the Parties. 
 ARTICLE 21.
GENERAL 
 21.1 Amendments 

No change, amendment, modification, extension, termination, or waiver of this Agreement, or any of the provisions herein contained, shall be
valid unless made in writing and signed by duly authorized representatives of the Parties hereto. 

  
 17 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT
IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 
  

 21.2 Force Majeure 

Neither Party shall be liable for any failure or delay in its performance under this Agreement due to causes, including, but not limited to,
acts of God, acts of civil or military authority, fires, epidemics, floods, earthquakes, riots, wars, sabotage, which are beyond its reasonable control; provided that the delayed Party: (i) gives the other Party written notice of such cause and
(ii) uses its reasonable efforts to correct such failure or delay in its performance. The delayed Party’s time for performance or cure shall be extended for a period equal to the duration of the cause. 

21.3 Relationship of Parties 

The Parties to this Agreement are independent contractors. Neither Party nor its respective employees, consultants, contractors or agents are
agents, employees or joint ventures of the other, nor do they have any authority to bind the other by contract or otherwise to any obligation. Neither Party will represent to the contrary, either expressly, implicitly, by appearance or otherwise.

 21.4 Assignment 

Neither this Agreement nor any rights or benefits hereunder shall be assignable or transferable by either Party without the prior written
consent of the other Party, which consent shall not be unreasonably withheld. In addition, either Party may assign this Agreement without such consent to a successor entity resulting from its merger, acquisition or the sale of all or substantially
all of the capital stock or assets of such Party. Any assignment not in accordance with this paragraph shall be void. This Agreement shall be binding upon and inure to the benefit of the successors and permitted assigns of the Parties. 

21.5 Governing Law and Venue 

This Agreement and all matters connected with the performance thereof shall be governed by and construed and enforced in accordance with the
laws of the State of California without regard to conflict of laws provisions, except that any dispute with respect to infringement, validity, or enforceability of any patent or published patent application shall be governed by and construed and
enforced in accordance with the laws of the jurisdiction in which such patent is issued or such patent application is published. Any litigation or other dispute resolution between the Parties relating to this Agreement shall take place in
California. By executing this Agreement, the Parties consent to personal jurisdiction of, and venue within, the state and federal courts of the State of California. The Parties agree that the provisions of the United Nations Convention on Contracts
for the International Sale of Goods will not apply to this Agreement or to the transactions conducted under this Agreement. 
 21.6
Export Control Laws 
 Each Party will observe all applicable United States and foreign laws with respect to the transfer of the
Products and related technical data to foreign countries, including, without limitation, the International Traffic in Arms Regulations (ITAR) and the Export Administration Regulations. 

21.7 Interpretation 

Whenever required by the context, the singular term shall include the plural, the plural term shall include the singular, and the gender of
any pronoun shall include all genders. Whenever the last day for the exercise of any privilege or the discharge of any duty hereunder shall fall on a Saturday, Sunday, or national or local holiday, the Party having such privilege or duty shall have
until 5:00 pm on the next succeeding business day to exercise such privilege or to discharge such duty. It is further agreed that no usage of trade or other regular practice between the Parties hereto shall be used to interpret or alter the terms of
this Agreement. Since the Parties have participated jointly in the negotiation and drafting of this Agreement, in the event an ambiguity or question of interpretation arises, no presumption or burden of proof shall arise favoring or disfavoring any
Party by virtue of authorship of any provision of this Agreement. 

  
 18 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT
IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 
  

 21.8 Severability 

If for any reason a court of competent jurisdiction finds any provision of this Agreement, or portion thereof, to be unenforceable, that
provision of the Agreement shall be enforced to the maximum extent permissible so as to effect the intent of the Parties, and the remainder of this Agreement shall continue in full force and effect. 

21.9 No Waiver 
 Failure
by either Party to enforce any provision of this Agreement shall not be deemed a waiver of future enforcement of that or any other provision. 

21.10 Counterparts 
 This
Agreement may be executed in one or more counterparts, each of which will be deemed an original, but all of which will constitute but one and the same instrument. 

21.11 Complete Agreement 

This Agreement, including all Exhibits, constitutes the entire agreement between the Parties with respect to the subject matter hereof, and
supersedes and replaces all prior or contemporaneous understandings or agreements, written or oral, regarding such subject matter, including the CDA, which is hereby terminated. No amendment to or modification of this Agreement shall be binding
unless in writing and signed by a duly authorized representative of both Parties. 
 21.12 Third Party Beneficiaries 

No third party beneficiary rights are conferred or are intended to be conferred by this Agreement. 

21.13 Headings 
 Headings
in this Agreement are for convenience only, and shall not be used to and shall not affect the meaning or interpretation of this Agreement. 

21.14 Full Disclosure/Authorization 

The statements and representations and commitments made by BIOTIUM in this Agreement or any Exhibit hereto do not contain any untrue statement
of a material fact or omit any material fact necessary in order to make the statements contained therein misleading. 
 21.15
Rights in Bankruptcy. 
 All licenses and other rights granted under or pursuant to this Agreement by BIOTIUM are, and shall
otherwise be deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code, licenses of right to “intellectual property” as defined under Section 101 of the U.S. Bankruptcy Code. The Parties agree that
LICENSEE, as licensee of certain rights under this Agreement, shall retain and may fully exercise all of its rights and elections under the U.S. Bankruptcy Code. 

Signature Page Follows 

  
 19 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT
IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 
  

 Each of the undersigned represents and warrants that he is duly authorized to execute this Agreement and
thereby bind his respective Party and that all required approvals have been obtained for the execution of this Agreement, which Agreement shall be binding on the Parties as of the Effective Date. For purposes hereof, a facsimile of a signed copy
shall have the same force and effect as an original signed Agreement. 
  

											
		 	BIOTIUM, INC.	 	LICENSEE: CYTEK BIOSCIENCES, INC.
						
		 	By:	 	/s/ Dr. Fei Mao	 		 	By:	 	/s/ WenBin Jiang, Ph.D.
				
		 	Name/Title: Dr. Fei Mao	 		 	Name/Title: WenBin Jiang, Ph.D.
		 	                    President and CEO	 		 	                    Chief Executive Officer
				
		 	Date: September 17, 2020	 		 	Date: September 16, 2020

  
 20 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT
IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 
  

 EXHIBIT A: BIOTIUM PRODUCT AND
DISCOUNT PRICE 
 Biotium Products available to be supplied under this Agreement, as set forth in Article 3 (scope of
agreement), are identified in the following Exhibit. Pursuant to Section 4.1 (Price), BIOTIUM agrees to offer Biotium Product at Price listed in this Exhibit. 

BIOTIUM PRODUCT EXHIBIT 
  

													
	Part
No.	 	Product Name	 	Unit Size	 	Quantity	 	Leadtime	 	U.S. List
Price
(2020)	 	Discount
Off List
Price (%)
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 	[***]	 	[***]	 	[***][***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

  
 21 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT
IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 
  

 EXHIBIT B: UPFRONT FEES AND
ROYALTY 
 In consideration of the rights granted under this Agreement, LICENSEE shall pay a
one-time non-refundable, non-creditable license upfront fee relating to the license of Biotium Products for FIELD OF USE as
specified below. 
 LICENSEE shall have the option to license additional Biotium Product(s) at a later time upon signing of an addendum to this Agreement
and paying additional license fee. 
 LICENSEE shall have the option to license Biotium Product(s) for DIAGNOSTICS FIELD OF USE added at a later time upon
signing of an addendum to this Agreement and paying additional license fee. 
  

					
	Biotium Products	  	Amount of fee	  	Due date
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]

 Royalty Report 
 In
further consideration of the rights granted under this Agreement, LICENSEE shall pay BIOTIUM a running royalty of [***] of LICENSEE’s worldwide NET SALES of Licensed Products sold in the FIELD OF USE under this Agreement from the EFFECTIVE
DATE. 
 Royalty payments shall be payable to BIOTIUM within [***] days following the end of each [***] in which the corresponding Licensed Products are
sold or otherwise transferred for compensation to a third party, and shall be sent to BIOTIUM in conjunction with the report due to BIOTIUM under Section 10.5 (royalty reporting). No royalties shall be due for free replacements or nominal
quantities of free samples, or internal routine testing of nominal quantities of Licensed Products for purposes of quality control, product development, product testing, sales demonstrations, collaborations and other
non-revenue generating uses of Licensed Products. 

  
 22 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT
IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 
  

 EXHIBIT C 

CERTIFICATE OF ANALYSIS 

[***] 
  

			
	[***]	  	[***]
		
	[***]	  	[***]
		
	[***]	  	[***]
		
	[***]	  	[***]
		
	[***]	  	[***]
		
	[***]	  	[***]
		
	[***]	  	

  

					
	 	  	[***]	  	[***]
	[***]	  	[***]	  	 
	[***]	  	[***]	  	 
	[***]	  	[***]	  	 
	[***]	  	[***]	  	 
	[***]	  	[***]	  	 

 [***] 
 [***] 

 
 [***] 

 

	
	 
	[***]

  
 23 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT
IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 
  

 [***] 
  

			
	[***]	  	[***]
		
	[***]	  	[***]
		
	[***]	  	[***]
		
	[***]	  	[***]
		
	[***]	  	[***]
		
	[***]	  	[***]
		
	[***]	  	

  

					
	 	  	[***]	  	[***]
	[***]	  	[***]	  	 
	[***]	  	[***]	  	 
	[***]	  	[***]	  	 
	[***]	  	[***]	  	 
	[***]	  	[***]	  	 

 [***] 
 [***] 

 
 [***] 

 

	
	 
	[***]

  
 24 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT
IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 
  

 [***] 
  

			
	[***]	  	[***]
		
	[***]	  	[***]
		
	[***]	  	[***]
		
	[***]	  	[***]
		
	[***]	  	[***]
		
	[***]	  	[***]
		
	[***]	  	

  

					
	 	  	[***]	  	[***]
	[***]	  	[***]	  	 
	[***]	  	[***]	  	 
	[***]	  	[***]	  	 
	[***]	  	[***]	  	 
	[***]	  	[***]	  	 

 [***] 
 [***] 

 
 [***] 

 

	
	 
	[***]

  
 25 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT
IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 
  

 [***] 
  

			
	[***]	  	[***]
		
	[***]	  	[***]
		
	[***]	  	[***]
		
	[***]	  	[***]
		
	[***]	  	[***]
		
	[***]	  	[***]
		
	[***]	  	

  

					
	 	  	[***]	  	[***]
	[***]	  	[***]	  	 
	[***]	  	[***]	  	 
	[***]	  	[***]	  	 
	[***]	  	[***]	  	 

 [***] 
  

[***] 
  

	
	 
	[***]

  
 26 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT
IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 
  

 [***] 
  

			
	[***]	  	[***]
		
	[***]	  	[***]
		
	[***]	  	[***]
		
	[***]	  	[***]
		
	[***]	  	[***]
		
	[***]	  	[***]
		
	[***]	  	

  

					
	 	  	[***]	  	[***]
	[***]	  	[***]	  	 
	[***]	  	[***]	  	 
	[***]	  	[***]	  	 
	[***]	  	[***]	  	 

 [***] 
  

[***] 
  

	
	 
	[***]

  
 27 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT
IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 
  

 [***] 
  

			
	[***]	  	[***]
		
	[***]	  	[***]
		
	[***]	  	[***]
		
	[***]	  	[***]
		
	[***]	  	[***]
		
	[***]	  	[***]
		
	[***]	  	

  

					
	 	  	[***]	  	[***]
	[***]	  	[***]	  	 
	[***]	  	[***]	  	 
	[***]	  	[***]	  	 

 [***] 
  

[***] 
  

	
	 
	[***]

  
 28 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT
IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 
  

 EXHIBIT D: BIOTIUM LICENSED PATENTS 

PATENT EXHIBIT 
  

					
	 	 	 
	Title	  	Patent/Publication#	  	Issue Date
	[***]	  	[***]	  	[***]
	  	[***]	  	[***]
	  	[***]	  	[***]
	  	[***]	  	[***]
	  	[***]	  	[***]
	
[***]
	  	[***]	  	[***]
	  	[***]	  	[***]
	  	[***]	  	[***]
	  	[***]	  	[***]

 TRADEMARK EXHIBIT 
  

							
	Trademark	  	Registration No.	  	Date of Registration	  	Classification
	CFO®	  	5,306,048	  	10/10/2017	  	Class 1

  
 29 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT
IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 
  

 Exhibit E: Limited Use Label License Statement 

Purchase of this product includes an immunity from suit under patents specified in the product insert to use only the amount purchased for RESEARCH and ASR
use. The use of this product for providing medical, therapeutic or diagnostic testing is expressly excluded. For more information contact Biotium, Inc. at btinfo@biotium.com. 

  
 30 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT
IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 
  

 Exhibit F: Materials Specifications Sheet 

See attached 

  
 31 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT
IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 
  

 [***] 
  

	
	 
	
[***]

	 [***]

	 [***]

	 [***]

	 [***]

	 [***]

	 [***]

	 [***]

	 [***]

	 [***]

 [***] 
 [***]

  
 32 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT
IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 
  

 [***] 
 Human
peripheral lymphocytes stained with cFluor 
 YG584 CD4. Staining with an Isotype control, 

cFluor YG584 Mouse IgGl, K (Catalog number: R7- 

20XXX) is shown in the open histogram. 
 [***] 

 
 

 
 [***] 
 [***]

 [***] 

  
 33 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT
IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 
  

 [***] 
  

	
	 
	
[***]

	 [***]

	 [***]

	 [***]

	 [***]

	 [***]

	 [***]

	 [***]

	 [***]

	 [***]

	 [***]

	 [***]

 [***] 
 [***]

 [***] 
 [***] 

  
 34EX-10.12

 Exhibit 10.12 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE
REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 
 SETTLEMENT, LICENSE, AND EQUITY ISSUANCE AGREEMENT 

This SETTLEMENT, LICENSE, AND EQUITY ISSUANCE AGREEMENT (this “Agreement”) is made and entered into as of October 5,
2020 (the “Effective Date”), by and between Becton, Dickinson and Company, a New Jersey corporation having a place of business at 1 Becton Drive, Franklin Lakes, New Jersey 07417, (“BD”), and Cytek Biosciences Inc.,
a Delaware corporation having a place of business at 46107 Landing Parkway, Fremont, California 94538 (“Cytek”). BD and Cytek are each referred to herein as a “Party,” and collectively as the
“Parties.” 
 RECITALS 

WHEREAS, the Parties are involved in a litigation styled Becton, Dickinson and Company v. Cytek Biosciences, Inc. et al., that is
currently pending in the United States District Court for the Northern District of California (Case No 3:18-cv-00933-MMC) (the
“Litigation”); 
 WHEREAS, the Parties wish to fully and finally settle and release any and all Claims (defined
below), whether known or unknown, as of the Effective Date based on any acts occurring, in whole or in part, prior to the Effective Date, including without limitation, any Claims arising from patent infringement, copyright infringement, antitrust
violations or otherwise; and 
 WHEREAS, as part of the resolution, BD is willing to grant a license, covenant not to sue and general
release, Cytek is willing to grant a general release, pay royalties, and issue equity, and Individual Defendants are willing to grant a general release pursuant to the terms set forth in this Agreement or the separate settlement agreement between BD
and the Individual Defendants. 
 NOW, THEREFORE, for and in consideration of the covenants, conditions and undertakings set forth in
this Agreement, it is hereby agreed by and among the Parties as follows: 
 ARTICLE 1 

DEFINITIONS 
 As
used herein, the following terms will have the following meanings: 
  

	1.1	 “Affiliate” shall mean, with respect to a Party, any Person that, directly, or indirectly
through one or more intermediaries, controls, is controlled by, or is under common control with, such Party; where “control” means (a) the ownership, directly or indirectly, of at least fifty percent (50%) (or maximum amount permitted
by applicable law) of the voting securities or other ownership interests of such Person, or (b) possession, directly or indirectly, of the power to affirmatively direct, or cause the direction of, the management or policies of such Person or
Party, whether through ownership of voting securities, by contract relating to voting rights or corporate governance. 

  

	1.2	 “BD Patent” shall mean any issued patent anywhere in the world owned by BD as of the Effective
Date, and any reissues, renewals, substitutions or extensions thereof. 

  

	1.3	 “Change of Control” shall mean any of the following: (a) a transaction or series of
related transactions in which a Person, or a group of related Persons, acquires from stockholders of Cytek shares representing more than fifty percent (50%) of the outstanding voting power of Cytek (a “Stock Sale”); (b) a
transaction that qualifies as a “Deemed Liquidation Event” as defined in the Charter; (c) the sale, transfer, exclusive license or other disposition, in one transaction or a series of transactions, of all or substantially all
of the intellectual property of Cytek; or (d) the sale, transfer, license or other disposition, in one transaction or a series of transactions, of all or substantially all of the assets relating to Cytek’s flow cytometer business.

  

	1.4	 “Charter” shall mean Cytek’s Amended and Restated Certificate of Incorporation, as
amended from time to time. 

  
 1 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT
IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 
  

	1.5	 “Claims” shall mean any claims, counterclaims, cross-claims, defenses, allegations, demands,
debts, dues, liabilities, requests for declaratory relief, proceedings, actions or causes of action of any kind and of whatsoever nature or character, regardless of whether existing in the past or present (or whether accrued, actual, contingent,
latent or otherwise), known or unknown, made or brought for the purpose of recovering any damages or royalties or obtaining any equitable relief or any other relief of any kind, including without limitation any and all of the foregoing that were
alleged or could have been alleged, as of the Effective Date, in the Litigation, or that are based in whole or in part on events occurring before the Effective Date, and any and all claims for reimbursement of legal fees, costs and disbursements
that were sought or could have been sought in the Litigation. 

  

	1.6	 “Common Stock” shall mean Cytek’s Common Stock, $0.001 par value per share.

  

	1.7	 “Current Cytek Instruments” shall mean (i) Cytek’s [***] that, as of the Effective
Date, are branded, marketed and sold, in each case, by or on behalf of Cytek, as the [***] in the hardware and software configurations existing in such branded, marketed and sold systems as of the Effective Date (the current specifications of which
are found in Exhibit A), and (ii) Cytek’s [***] that are branded, marketed and sold, in each case, by or on behalf of Cytek, and that are [***] where such [***] may include improvements, updates or modifications that provide
improvement in functionality not more than [***] than the functionality of the systems listed in (i). A product that is (1) manufactured [***] from a design received in substantially completed form from a Third Party for resale to only that
Third Party (or for resale only as that Third Party directs) or (2) not manufactured by Cytek or any of its Affiliates, does not, in each case of (1) and (2), constitute a Current Cytek Instrument. 

 

	1.8	 “Cytek’s Fully Diluted Equity” shall mean the outstanding fully-diluted equity of Cytek
as of the Effective Date (assuming exercise or conversion of all outstanding options, warrants, or other rights or agreements to purchase or acquire capital stock, or any outstanding securities convertible into or exchangeable for capital stock, of
Cytek as of the Effective Date). 

  

	1.9	 “Effective Date” shall mean the effective date of this Agreement as set forth in the preamble
above. 

  

	1.10	 “Individual Defendants” are Ming Yan, Alfred Riley, David Vrane, Zhenyu Zhang, Zhenxiang Gong,
Alex Zhong, Maria Jaimes, Gil Reinen, and Janelle Shook. 

  

	1.11	 “Licensed Patents” shall mean (a) U.S. Patent No. 6,683,314, (b) U.S. Patent
No. 6,809,804, (c) U.S. Patent No. 7,129,505, and (d) U.S. Patent No. 10,481,074, and all continuations, divisionals, continuations-in-part,
reissues, foreign counterparts, or patents claiming priority to the four identified patents. 

  

	1.12	 “Licensed Product” shall mean any of Cytek’s [***] sold, leased or similarly transferred
as a Cytek product for consideration by or on behalf of Cytek, or its Affiliates or its sublicensees to the extent permitted under Section 6.1, that, on or after the Effective Date, are branded, marketed and sold as a Cytek product by Cytek,
such Affiliate, or its sublicensees to the extent permitted under Section 6.1, including the [***]. A product that is manufactured predominantly from a design received in substantially completed form from a Third Party for resale to only that
Third Party (or for resale only as that Third Party directs) does not constitute a Licensed Product. 

  

	1.13	 “Net Sales” means, with respect to Cytek and a Royalty-Bearing Product, the total amount [***]
on sales, transfers, or leases of such Royalty-Bearing Product by Cytek or its Affiliates, or the total amount [***] on sales, transfers or leases by sublicensees of Cytek or its Affiliates to Third Parties, where such amounts [***]), in bona fide
arm’s length transactions (collectively, “Gross Sales”), when including the following deductions, and in each case related specifically to the Royalty-Bearing Product and actually allowed and taken by such Third Parties and not
otherwise recovered by or reimbursed to Cytek, its Affiliates or (sub)licensees: 

  
 2 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT
IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 
  

	 	(a)	 normal and customary trade, cash and quantity discounts; 

 

	 	(b)	 price reductions or rebates, imposed by, or otherwise paid to governmental authorities or negotiated with other
payees; 

  

	 	(c)	 taxes on sales (such as sales, value added, or use taxes) to the extent added to the sale price and set forth
separately as such in the total amount invoiced; 

  

	 	(d)	 amounts repaid or credited by reason of rejections, defects, return goods allowance, recalls or returns; and

  

	 	(e)	 freight, insurance, import/export, and other transportation charges to the extent added to the sale price and
set forth separately as such in the total amount invoiced. 

 In the case of a Combination Product (defined below), all
such discounts, allowances, credits, rebates, and other deductions shall be fairly and equitably allocated to the Royalty-Bearing Product and other products of Cytek, its Affiliates or (sub)licensees such that the Royalty-Bearing Product does not
bear a disproportionate portion of such deductions. 
 Net Sales shall not include transfers or dispositions [***] to the extent sold for
[***] thereof, but shall include [***]. 
 Net Sales shall include the amount or fair market value of [***] by such Party, its Affiliates or
(sub)licensees in respect of such Royalty-Bearing Product, whether [***]. Net Sales shall not include sales between or among [***], but shall include the [***]. For clarity, [***]. 

If a Royalty-Bearing Product is sold in combination with another product for a single price (a “Combination Product”), the Net
Sales for such Combination Product in such country or jurisdiction shall be calculated as follows, subject to the Deduction Limit: 

(A) If Cytek, its Affiliates, or (sub)licensee separately sells in such country or jurisdiction, the Royalty-Bearing Product in
such Combination Product with the other product(s) (the “Other Product”), the Net Sales attributable to such Combination Product shall be calculated based on the running average sales price of the stand-alone Royalty-Bearing
Product. 
 (B) If Cytek, its Affiliates, and (sub)licensees do not separately sell in such country or jurisdiction the
Royalty-Bearing Product but do separately sell Other Product in such Combination Product, the Net Sales attributable to such Combination Product shall be calculated by multiplying the Net Sales of such Combination Product by the fraction (D-E)/D where: “D” is the average Net Sales price during the period to which the Net Sales calculation applies for such Combination Product in such country or jurisdiction and “E”
is the average Net Sales price during the period to which the Net Sales calculation applies for such Other Product. 
 (C) If
Cytek, its Affiliates, and (sub)licensees do not separately sell in such country or jurisdiction the Royalty-Bearing Product or the Other Product, the Net Sales attributable to such Combination Product shall be determined based on the running
average global sales price of the stand-alone Royalty-Bearing Product. 
  

	1.14	 “Person” shall mean an individual, sole proprietorship, corporation, trust, partnership,
limited liability company, joint venture, unincorporated organization, government agency or any agency or political subdivision thereof, or other entity. 

  

	1.15	 “Preferred Stock” shall mean Cytek’s Preferred Stock, $0.001 par value per share.

  
 3 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT
IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 
  

	1.16	 “Reagent Co-Marketing Agreement” shall have the
meaning set forth in Section 6.3. 

  

	1.17	 “Royalty-Bearing Product” shall mean (a) [***], (b) [***], or (c) any other [***],
including [***]. 

  

	1.18	 “Third Party” shall mean any Person other than the Parties to this Agreement or their
respective Affiliates. 

  

	1.19	 “Voting Agreement” shall mean that certain Amended and Restated Voting Agreement among Cytek
and certain stockholders of Cytek, dated as of September 7, 2018, as amended from time to time. 

 ARTICLE 2

 DISMISSAL 
  

	2.1	 General Dismissal of Litigation. Within no later than three (3) business days following the
Effective Date, the Parties shall request dismissal of the Litigation with prejudice by filing the form of dismissal attached hereto as Exhibit B or by such other procedure as agreed to between the Parties or which may be necessary to dismiss
the Litigation. 

  

	2.2	 No Fees, Costs, or Expenses. No Party shall owe any other Party costs, expenses and fees incurred in
connection with such Litigation and the dismissal thereof under the terms of this Agreement, except as otherwise expressly provided in Article 4. The Parties acknowledge and agree that this Agreement is enforceable according to its terms with
respect to final dismissal with prejudice of all Claims asserted by the Parties in the Litigation. 

  

	2.3	 Destruction of BD Confidential Documents. Within [***] of the Effective Date, Cytek shall destroy and
render unrecoverable any and all documents identified in Exhibit C (collectively, “BD Confidential Documents”). Cytek shall certify compliance with this Section in writing using the form of Exhibit D by the [***]
following the Effective Date. The obligations under this Section 2.3 shall be in addition to any obligations arising under protective orders under the Litigation. 

ARTICLE 3 
 PATENT
RELATED COVENANTS 
  

	3.1	 BD Covenant Not to Sue. Subject to Section 4.3, BD hereby covenants that it shall not enforce, or
permit or encourage the enforcement of, against Cytek, or its Affiliates, (sub)licensees, directors, employees, distributors, vendors, purchasers, end users, customers, successors or assigns (each, a “Cytek Protected Person”) any BD
Patents against any such Cytek Protected Person in connection with the development, manufacture, use, importation, offer for sale or sale of Current Cytek Instruments (“Covenant Not to Sue”). Such covenant shall also apply to any
person or entity to whom BD assigns such patent or grants a right to enforce such patent. For the avoidance of any doubt, this Covenant Not to Sue does not apply to a product that is not a Current Cytek Instrument. 

 

	3.2	 Cytek No Challenge. The Covenant Not Sue granted under Section 3.1 shall terminate with respect to
any claim of any BD Patent in the event a Cytek Protected Person disputes or challenges in a legal proceeding the validity, enforceability or scope of such claim, except in the event BD, its Affiliates, and any other Person having a right to do so
commences a proceeding in a court of law to enforce such claim against a Cytek Protected Person. Further, if a patent owned or controlled by any Cytek Protected Person is in prosecution and is rejected on the basis of a BD Patent, such Cytek
Protected Person shall have the right to distinguish the inventions claimed in such patent from those claimed in such BD Patent. 

  
 4 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT
IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 
  

 ARTICLE 4 

PAYMENT AND ROYALTIES 
  

	4.1	 Settlement Payment. In consideration of the rights granted to the Parties under this Agreement, Cytek
shall remit to BD a non-refundable one-time payment of USD $[***] on the Effective Date hereof (“Settlement Payment”). Settlement Payment shall be made
in accordance with the Payment details identified below in Section 4.7. 

  

	4.2	 Change of Control Payment. Upon the closing of a Change of Control, Cytek shall pay to BD an amount
equal to (a) if [***], [***] dollars ($[***]), (b) if the agreement pursuant to which the Change of Control occurs is executed within [***] of the Effective Date, [***] dollars ($[***]), or (c) if clause (b) is inapplicable and [***],
[***] dollars ($[***]) ((a), (b) or (c), the “Change of Control Payment”). The Change of Control Payment shall be made in accordance with the payment details identified below in Section 4.7. 

 

	4.3	 Settlement Royalties. Subject to the terms of this Agreement, Cytek shall pay BD a [***] royalty of
[***] percent ([***]%) on Net Sales of Royalty-Bearing Products[***] beginning on [***] and ending on the tenth (10th) anniversary of the Effective Date (“Settlement Royalties”). Settlement Royalties payable under this
Section 4.3 shall be due within [***] days of the end of [***]. In the event that BD or any of its Affiliates files against any Cytek Protected Person a claim covered by the Covenant Not to Sue in Section 3.1 in any court, any future
Settlement Royalties shall not be owed for any Royalty-Bearing Product that [***]. 

  

	4.4	 [***] Sale Payment. Upon the earlier to occur of (a) [***] days after the sale of an aggregate of [***]
units of the Royalty-Bearing Products [***] (including sales made [***]), or (b) the closing of a Change of Control, Cytek shall pay to BD a non-refundable one-time
payment of USD $[***]. 

  

	4.5	 No Representation of a Reasonable Royalty. The Parties agree that the Settlement Payment and Settlement
Royalties are a litigation settlement, and no representation is made that the foregoing consideration represents a reasonable royalty or any other appropriate quanta of damages for any infringement alleged in the Litigation. 

 

	4.6	 No Reduction. For the avoidance of doubt, Cytek shall not be entitled to take any reduction in the
royalty payable under Section 4.3 above for Royalty-Bearing Products for [***]. 

  

	4.7	 Payment Details. All amounts payable hereunder shall be paid by wire transfer to BD to the following
account, or such other account as BD may designate at least three (3) business days prior to any payment date: 

BANK NAME: [***] 
 BANK ADDRESS:
[***] 
 ACCOUNT NAME: [***] 

ACCOUNT NUMBER: [***] 
 ABA/ACH
ROUTING: [***] 
 SWIFT (If International): [***] 
  

	4.8	 Cost of Payment. Any costs for making a payment under this Agreement, including Settlement Payment and
Settlement Royalties, shall be borne [***]. 

  

	4.9	 Currency. All amounts payable hereunder shall be payable in United States Dollars. Amounts based on
which royalties or other payments are calculated that are in currencies other than U.S. Dollars shall be converted to U.S. Dollars based on the New York rate of exchange as quoted in The Wall Street Journal five (5) business days prior to the
date that payment is due. If not so published, the Parties may agree on a substitute publication. If, due to restrictions or prohibitions imposed by national or international authority, payments cannot be made as provided in this Agreement, the
Parties will consult with a view to finding a prompt and acceptable solution. 

  
 5 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT
IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 
  

	4.10	 No BD Payments. For clarity, BD shall owe no payment to Cytek under this Agreement, the sufficiency of
which is acknowledged by Cytek. 

 ARTICLE 5 

ROYALTY REPORTS 
  

	5.1	 Royalty Reports. Cytek shall, within [***] days after the end of [***] ([***] days after [***]) of each
year, deliver to BD a true and accurate royalty report for Royalty-Bearing Products. Each such report shall give the following particulars of the Net Sales, on a Royalty-Bearing Product by Royalty-Bearing Product basis: 

 

	 	(a)	 the [***] and [***] of Royalty-Bearing Products, [***] based on whether the [***] of Royalty Bearing Products
[***] during the most recently completed [***] for which a royalty is due under Section 4.3 above; 

  

	 	(b)	 [***] the Royalty-Bearing Products, [***] as indicated under above, [***]; 

 

	 	(c)	 [***] Royalty-Bearing Products, [***] as indicated under (a) above, [***]; and 

 

	 	(d)	 if no [***] have been made by Cytek during any reporting period, Cytek shall so report. 

Cytek shall also report to BD, in the [***] report due to BD, when Cytek has sold its [***] Royalty-Bearing Product. 

 

	5.2	 Correctness and Payment. The correctness and completeness in all material respects of each such report
shall be attested to in writing by a responsible financial employee of Cytek (but without any personal liability) or by Cytek’s external auditor. Simultaneously with the delivery of each such royalty report, Cytek shall pay BD the royalty and
any other payments due under this Agreement for the period covered by such report. All payments not made when due hereunder shall accrue interest at the Prime Rate to the extent legally permitted. “Prime Rate” shall mean the average
prime rate published in the Wall Street Journal during the relevant period (calculated by dividing (a) the sum of the prime rates for each of the days during the relevant period, by (b) the number of days in the relevant period).

  

	5.3	 Books and Records. Cytek shall keep such books of account containing complete and accurate particulars
as may be reasonably necessary for the purposes of showing the amounts payable to BD. No more than [***], Cytek shall make such books of account available at Cytek’s principal place of business (no more than [***] upon reasonable prior written
notice by BD to Cytek) for inspection, during reasonable business hours, by BD and/or its designated accounting firm for the purpose of verifying payments due to BD under this Agreement, provided that BD shall provide Cytek with [***] advance notice
and such inspection shall occur during normal business hours on a day mutually agreed by the Parties. BD shall be responsible for the cost of any such inspection; provided, however, that if an inspection establishes conclusively for any audited
period an underpayment in excess of [***] of Settlement Royalties due to BD hereunder, then Cytek shall reimburse BD for the reasonable, documented out-of-pocket costs
incurred by BD to conduct the inspection. In addition, Cytek shall pay BD the shortfall plus interest within [***] days after the conclusion of the audit. 

  
 6 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT
IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 
  

 ARTICLE 6 

LICENSE; FUTURE COLLABORATIONS 
  

	6.1	 License Grant to Cytek. BD hereby grants to Cytek and its controlled Affiliates a non-exclusive, irrevocable, perpetual, worldwide, and non-transferrable license (other than as set forth in Section 4.3) under the Licensed Patents to make, have made
(pursuant to the sublicensing rights granted in the last sentence of this Section 6.1), use, import, sell, offer for sale, and have sold Licensed Products marked as set forth in Section 6.2 (“Patent License”). This Patent
License shall inure to the benefit of any purchaser of or successor to Cytek and such controlled Affiliates, whether by sale of stock, equities or assets or by merger or reorganization, but shall extend to only (a) the Licensed Products that
existed at Cytek and such controlled Affiliates prior to the purchase, merger, or succession transaction and (b) products of such purchaser or successor (i) that would meet the definition of “Licensed Product” if such
product were sold by Cytek and such controlled Affiliates and (ii) that exist after the purchase, merger, or succession transaction. For the avoidance of doubt, any Persons that are no longer Affiliates of such purchaser or successor will no
longer be granted the benefit of this Patent License and all rights under the Patent License shall immediately terminate and cease on a prospective basis with respect to such Person. Cytek or such controlled Affiliates may grant sublicenses to one
(1) or more Third Party sublicensees to make, import, sell, or offer for sale one or more Licensed Products solely at the request of and for the benefit of Cytek and such controlled Affiliates on prior written notice to BD (such notice to
include details of the identity of such Third Party sublicensee together with the operating territory and address of such sublicensee), but such sublicenses shall extend to only (x) the Licensed Products that are made, imported, sold, or
offered for sale after the grant of such sublicense and (b) products of Cytek and such controlled Affiliates that would meet the definition of “Licensed Product” if such product were sold by Cytek and such controlled
Affiliates. 

  

	6.2	 Marking. Cytek shall mark the Licensed Products by referencing or linking to a Cytek webpage that
contains a list of the following U.S. Patents: 6,683,314; 6,809,804; 7,129,505; and 10,481,074 owned by Becton, Dickinson and Company, in each case prior to the respective expiration date of such patents. 

 

	6.3	 [***] Beginning on [***], Cytek and BD shall enter [***], with the understanding that neither party is under
any obligation to agree [***]. 

 ARTICLE 7 

RELEASES 
  

	7.1	 BD Release. BD, on behalf of itself and each of its Affiliates, and each of its and their licensors,
predecessors, successors-in-interest, assigns, officers, directors, managers, members, stockholders, experts, consultants, attorneys, representatives, heirs, agents and
employees, and all Persons acting by, through, under or in concert with any of the foregoing (collectively, the “BD Parties”), hereby fully, finally and forever releases, acquits and discharges Cytek and its controlled Affiliates,
and each of its and their licensors, predecessors, successors-in-interest, assigns, officers, directors, managers, members, stockholders, experts, consultants,
attorneys, representatives, heirs, agents and employees, and all Persons acting by, through, under or in concert with any of foregoing (collectively, the “Cytek Parties”) and each of the Individual Defendants, from any and all
Claims, whether known or unknown, as of the Effective Date, against the Cytek Parties, or any of them, that in any way relate to or arise, in whole or in part, out of any act occurring prior to the Effective Date. 

 

	7.2	 Cytek Release. Cytek, on behalf of itself and each of the Cytek Parties, hereby fully, finally, and
forever releases, acquits and discharges the BD Parties from any and all Claims, whether known or unknown, as of the Effective Date, against the BD Parties, or any of them, that in any way relate to or arise, in whole or in part, out of any act
occurring prior to the Effective Date. 

  
 7 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT
IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 
  

	7.3	 California Civil Code 1542. The settlement and releases in this Agreement include an express, informed,
knowing and voluntary waiver and relinquishment to the fullest extent permitted by law. In this connection, the Parties acknowledge that they may have sustained damages, losses, costs or expenses which are presently unknown and unsuspected and that
such damages, losses, costs or expenses as may have been sustained may give rise to additional damages, losses, costs or expenses in the future. The Parties hereto further acknowledge that they have negotiated this Agreement taking into account
presently unsuspected and unknown claims, counterclaims, causes of action, damages, losses, costs and expenses, and the Parties hereto voluntarily and with full knowledge of its significance, expressly waive and relinquish any and all rights they
may have under any state or federal statute, rule or common law principle, in law or equity, relating to limitations on general releases. The Parties voluntarily and with full knowledge of its significance, expressly waive and relinquish any and all
rights they may have under any state or federal statute, rule or common law principle, in law or equity, relating to limitations on releases. Specifically, each Party hereby expressly waives any rights it may have under California Civil Code
Section 1542 (or any other similar law in any jurisdiction), which provides that: “A general release does not extend to claims which the creditor or releasing party does not know or suspect to exist in his or her favor at the time of
executing the release and that, if known by him or her, would have materially affected his or her settlement with the debtor or released party.” 

ARTICLE 8 

TERMINATION 
  

	8.1	 Termination. Except as otherwise expressly provided herein (including without limitation Sections 3.1
and 6.1), this Agreement shall not terminate unless otherwise agreed upon by the Parties in writing. Notwithstanding the foregoing, Articles 13.2 and 13.3 shall terminate upon the earlier to occur of the consummation of a Change of Control, a
“Qualified IPO,” as such term is defined in the Charter as of the Effective Date, or an initial firm-commitment underwritten public offering in connection with which all then outstanding shares of Preferred Stock are converted into
Common Stock. In the event of any breach of this Agreement, a Party may, after carrying out dispute resolution as set forth in Article 12, seek enforcement of its rights under this Agreement (including without limitation specific performance or
reasonable attorney’s fees sought in connection therewith). 

  

	8.2	 Survival. In the event the parties agree in writing to terminate this Agreement, the following
provisions shall survive the termination of this Agreement along with any other provision which by their context are intended to survive: Article 1, Article 2, Article 4, Article 5 (with respect to payments owing under Article 4), Article 7,
Section 8.1, Section 8.2, Section 9.1, Section 9.2, and Article 11. 

 ARTICLE 9 

CONFIDENTIALITY; PRESS RELEASE 
  

	9.1	 Obligation of Confidentiality. No Party and none of its Affiliates will disclose (i) the terms of
this Agreement; (ii) the content of the Parties’ discussions and negotiations regarding this Agreement; or (iii) any documents or correspondence exchanged between the Parties in connection with their discussions or negotiations
regarding this Agreement except: 

  

	 	(a)	 with the prior written consent of the other Parties; 

 

	 	(b)	 if required to enforce such Party’s rights under this Agreement; 

 

	 	(c)	 to such Party’s accountants, legal counsel, tax advisors and other financial or legal advisors, in each
case who are bound by written confidentiality and non-use provisions no less restrictive than those contained in this Section 9.1; 

  
 8 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT
IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 
  

	 	(d)	 to any governmental body having jurisdiction and specifically requiring such disclosure; provided, however,
that prior to any such disclosure pursuant to this Section 9.1(d) the Party seeking disclosure will promptly notify the other Parties, and seek and consider in good faith the other Parties’ input regarding whether there may be provisions
of this Agreement with respect to which the disclosing Party might seek confidential treatment; 

  

	 	(e)	 in response to a valid subpoena or as otherwise may be required by law; provided, however, that prior to any
such disclosure pursuant to this Section 9.1(e), the Party seeking disclosure will promptly notify the other Parties, and take all reasonable actions to minimize the nature and extent of such disclosure, and to make such disclosure subject to
protective order under an “Outside Attorneys Eyes Only” or higher confidentiality designation; 

  

	 	(f)	 as required during the course of litigation and subject to the extent applicable to a protective order;
provided however, that any production under a protective order would be protected under an “Outside Attorneys Eyes Only” or higher confidentiality designation; 

 

	 	(g)	 for the purposes of disclosure in connection with the Securities and Exchange Act of 1934, as amended, the
Securities Act of 1933, as amended, and any other reports filed with the Securities and Exchange Commission, or any other filings, reports or disclosures that may be required under applicable laws or regulations; or 

 

	 	(h)	 with respect to either BD or Cytek, to its existing and prospective investors, existing and prospective
Affiliates and prospective acquirers and strategic partners (in each case together with their respective legal counsel, tax advisors and other financial or legal advisors), in each case who are bound by written confidentiality and non-use provisions no less restrictive than those contained in this Section 9.1 

  

	9.2	 Public Statements. BD and Cytek may make the following public statement relating to this Agreement:
“Becton, Dickinson and Company (BD) and Cytek Biosciences, Inc. (Cytek) reached an agreement to settle their ongoing litigation in the U.S. District Court for the Northern District of California. As part of the settlement, all claims asserted
against Cytek and the individual defendants, as well as counterclaims asserted against BD, were dismissed. Cytek provided financial consideration to BD and received rights to certain BD patents. The terms of the agreement are otherwise
confidential.” 

 ARTICLE 10 

REPRESENTATIONS, WARRANTIES AND LIMITATION OF LIABILITY 
  

	10.1	 Mutual Representations and Warranties. Each Party to this Agreement represents and warrants to the
others that, as of the date hereof: 

  

	 	(a)	 Except as to the Individual Defendants, it is duly organized, validly existing and in good standing under the
laws of the jurisdiction of its organization, and has all requisite power and authority to execute, deliver and perform this Agreement on behalf of itself and its Affiliates. 

 

	 	(b)	 This Agreement is a legal, valid and binding obligation enforceable against such Party in accordance with its
terms and conditions. 

  
 9 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT
IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 
  

	 	(c)	 Its entry into this Agreement has been approved by all requisite corporate action, and that this Agreement and
the transactions contemplated hereby do not violate any other agreements to which it is subject as a party or otherwise bound. 

  

	 	(d)	 It has the right to grant the licenses, releases and covenants expressly granted by such Party as set forth in
this Agreement. 

  

	10.2	 Representations and Warranties of BD. BD represents and warrants that, as of the Effective Date:

  

	 	(a)	 It is the sole and lawful owner of all rights, title, and interests in and to the BD Patents and has the right
to grant the Covenant Not to Sue and the Patent License as contemplated hereby without violating or conflicting with any other agreements to which it is subject as a party or otherwise bound. 

 

	 	(b)	 The Shares to be acquired by BD will be acquired for investment for BD’s own account, not as a nominee or
agent, and not with a view to the resale or distribution of any part thereof, and BD has no present intention of selling, granting any participation in, or otherwise distributing the same. BD does not presently have any contract, undertaking,
agreement or arrangement with any Person to sell, transfer or grant participations to such Person or to any third Person, with respect to any of the Shares. 

  

	 	(c)	 BD understands that the Shares have not been, and will not be, registered under the Securities Act of 1933, as
amended (the “Securities Act”), by reason of a specific exemption from the registration provisions of the Securities Act which depends upon, among other things, the bona fide nature of the investment intent and the accuracy of
BD’s representations as expressed herein. BD understands that the Shares are “restricted securities” under applicable U.S. federal and state securities laws and that, pursuant to these laws, BD must hold the Shares indefinitely
unless they are registered with the Securities and Exchange Commission and qualified by state authorities, or an exemption from such registration and qualification requirements is available. BD acknowledges that Cytek has no obligation to register
or qualify the Shares. BD further acknowledges that if an exemption from registration or qualification is available, it may be conditioned on various requirements including, but not limited to, the time and manner of sale, the holding period for the
Shares, and on requirements relating to Cytek which are outside of the BD’s control, and which Cytek is under no obligation and may not be able to satisfy. 

 

	 	(d)	 BD understands that no public market now exists for the Shares, and that Cytek has made no assurances that a
public market will ever exist for the Shares. 

  

	 	(e)	 BD understands that the Shares and any securities issued in respect of or exchange for the Shares, may be
notated with one or all of the following legends: 

  

	 	(i)	 “THE SHARES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AND HAVE BEEN
ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH TRANSFER MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM SATISFACTORY TO
THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES ACT OF 1933.” 

  
 10 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT
IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 
  

	 	(ii)	 Any legend required by Cytek’s Bylaws. 

 

	 	(iii)	 Any legend required by the securities laws of any state to the extent such laws are applicable to the Shares
represented by the certificate, instrument, or book entry so legended. 

  

	 	(f)	 BD is an accredited investor as defined in Rule 501(a) of Regulation D promulgated under the Securities Act.

  

	 	(g)	 BD and its Affiliates are not aware of any Cytek Confidential Information that has been subject to any data
breach. 

  

	10.3	 Representations and Warranties of Cytek. Cytek, on behalf of itself and its Affiliates, represents and
warrants to BD that, as of the Effective Date, other than with respect to 10.3(b): 

  

	 	(a)	 Cytek and its Affiliates do not manufacture or sell any flow cytometers other than the Current Cytek
Instruments. 

  

	 	(b)	 Cytek and its Affiliates [***] units of the Royalty-Bearing Products to
end-users as of September 30, 2020. 

  

	 	(c)	 Cytek and its Affiliates are not aware of any BD Confidential Information that has been subject to any data
breach. 

  

	 	(d)	 The authorized capital of Cytek consists, immediately prior to the Effective Date, of: 

 

	 	(i)	 [***] shares of Common Stock, [***] shares of which are issued and outstanding immediately prior to the
Effective Date. 

  

	 	(ii)	 [***] shares of Preferred Stock, [***] of which have been designated Series A Preferred Stock, all of which are
issued and outstanding, [***] of which have been designated Series B Preferred Stock, [***] of which are issued and outstanding, and [***] of which have been designated Series C Preferred Stock, [***] of which are issued and outstanding immediately
prior to the Effective Date. The rights, privileges and preferences of the Preferred Stock are as stated in the Charter and as provided by the Delaware General Corporation Law. 

 

	 	(iii)	 Cytek has reserved [***] shares of Common Stock for issuance to officers, directors, employees and consultants
of Cytek pursuant to its 2015 Equity Incentive Plan (the “Stock Plan”), of which options to purchase [***] shares of Common Stock have been granted and are outstanding. 

 

	 	(e)	 Cytek’s summary capitalization table as of the Effective Date is set forth in Exhibit E hereto (the
“Cap Table”). 

  

	 	(f)	 Attached hereto as Exhibit F is a true, correct and complete copy of the Charter as of the Effective
Date. No action for any amendment or modification of the Charter is pending as of the Effective Date. 

  
 11 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT
IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 
  

	 	(g)	 Attached hereto as Exhibit G is a true, correct and complete copy of the bylaws of Cytek. The Bylaws are
in full force and effect on and as of the date hereof, and no action for any amendment, modification or rescission of such Bylaws is pending as of the Effective Date. 

 

	 	(h)	 Except for (i) the rights provided in Section 4 of that certain Amended and Restated Investors’
Rights Agreement, by and among Cytek and certain stockholders of Cytek, dated as of September 7, 2018, (ii) the securities described in Section 10.3(d) of this Agreement, and (iii) as otherwise identified in the Cap Table, there are
no outstanding options, warrants, rights (including conversion or preemptive rights and rights of first refusal or similar rights) or binding agreements, orally or in writing, to purchase or acquire from Cytek any shares of Common Stock or Preferred
Stock, or any securities convertible into or exchangeable for shares of Common Stock or Preferred Stock. 

  

	 	(i)	 Except as set forth in the Charter, Cytek has no obligation (contingent or otherwise) to purchase or redeem any
of its capital stock. 

  

	 	(j)	 All of the issued and outstanding shares of Common Stock and Preferred Stock (i) have been duly authorized
and validly issued, (ii) are fully paid and non-assessable, and (iii) were issued in compliance with all applicable federal and state securities laws. 

 

	 	(k)	 All corporate action required to be taken by Cytek’s Board of Directors and stockholders in order to
authorize Cytek to issue the Shares has been taken on or prior to the Effective Date. 

  

	 	(l)	 Cytek has obtained valid waivers of any rights by other parties to purchase any of the Shares issued under this
Agreement. 

  

	 	(m)	 Cytek has delivered to each Purchaser its audited financial statements for the fiscal year ended
December 31, 2018 and unaudited financial statements for the fiscal year ended December 31, 2019, and its unaudited financial statements (including balance sheet, income statement and statement of cash flows) through August 31, 2020
(collectively, the “Financial Statements”). The Financial Statements have been prepared in accordance with GAAP applied on a consistent basis throughout the periods indicated, except that the unaudited Financial Statements may not
contain all footnotes required by GAAP. 

  

	 	(n)	 Since August 31, 2020, there have been no events or circumstances that have had or would reasonably be
expected to result in a material adverse effect on the business, assets (including intangible assets), liabilities, financial condition, property or results of operations of Cytek. 

 

	10.4	 No Other Warranties. EACH PARTY HEREBY DISCLAIMS ANY OTHER WARRANTIES (INCLUDING WITHOUT LIMITATION
IMPLIED OR STATUTORY WARRANTIES) WITH RESPECT TO THE SUBJECT MATTER CONTAINED HEREIN, INCLUDING WITHOUT LIMITATION THE WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NONINFRINGEMENT OF THIRD PARTY RIGHTS, OR PATENT VALIDITY OR
ENFORCEABILITY. 

  
 12 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT
IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 
  

 ARTICLE 11 

NO ADMISSION OF LIABILITY 
  

	11.1	 No Liability. This Agreement is entered into by the Parties without any admission of misconduct,
responsibility, or liability, which are all expressly denied, and is entered into by the Parties solely for the purpose of settlement and compromise of the Litigation and any Claims arising out of or related to the Litigation. 

ARTICLE 12 
 DISPUTE
RESOLUTION 
  

	12.1	 Escalation to Senior Management. Each Party hereby agrees that it will first attempt in good faith to
resolve any dispute arising out of or relating to this Agreement promptly by negotiations. If after discussing the matter in good faith and attempting to find a mutually satisfactory resolution to the issue, the Parties are unable to resolve such
dispute, the matter will be referred to a representative from each Party with the authority to resolve the dispute for resolution. If, after such efforts, the Parties are unable to resolve such dispute within [***] of such matter being referred to
such representatives, the Parties agree to at least one professionally mediated session at a location and with a mediator to be agreed upon by the Parties. If such dispute is unable to be resolved by good faith negotiation and mediation within [***]
of such date that the dispute was referred to the representatives, the Parties agree to submit the dispute to binding arbitration pursuant to Section 12.2. 

 

	12.2	 Arbitration. Any controversy or claim arising out of or relating to this Agreement, except as set forth
in Section 4.3, that is unresolved pursuant to Section 12.1, shall be settled by final and binding arbitration before a panel of three (3) neutral arbitrators (one chosen by each Party and the third chosen by the other two) in
accordance with the then-current Commercial Arbitration rules of the American Arbitration Associate (“AAA”), except where those rules conflict with this Section 12.2, in which case this Section 12.2 controls. Any court
shall have the authority to enforce this clause and enter judgment on any award based on the arbitration panel’s decision. The arbitration panel may engage an independent expert with experience in the subject matter of the dispute to advise the
arbitrator. The party-appointed arbitrators shall be selected within [***] of commencement of the arbitration. The arbitration shall be held in Delaware unless otherwise agreed by the parties and the Panel, and in rendering the award the arbitration
panel must apply the substantive law of the State of Delaware (except where the law conflicts with this clause), except that the interpretation of this provision shall be governed by the Federal Arbitration Act. The arbitration panel in consultation
with the Parties shall establish a process for such arbitration. Each Party shall bear its own attorney’s fees and expert witness fees, and the Parties shall share equally the cost of the arbitration, including administrative and
arbitrators’ fees. 

 ARTICLE 13 

EQUITY GRANT 
  

	13.1	 Initial Equity Grant. On the Effective Date, Cytek shall issue to BD 1,565,698 shares of Common Stock
(the “Shares”) which shall represent no less than [***] percent ([***]%) of Cytek’s Fully Diluted Equity (the “Initial Equity Grant”), calculated after taking into account any adjustments to the Conversion
Price (as defined in the Charter) of any series of Preferred Stock (as defined in the Charter) in connection with the issuance of the Initial Equity Grant, pursuant to Article IV.B, Section 4 of the Charter. 

 

	13.2	 Adverse Company Actions. Cytek shall obtain the prior written consent of BD if it will, by amendment,
merger, consolidation, recapitalization, dividend, distribution, redemption or otherwise, take, authorize or approve any action that would, [***] pursuant to the terms of this Agreement in a manner [***] to any effect such action would have on the
other holders of shares of Common Stock (“Other Common Shares”), including any of the following actions, to the extent such actions would result in such [***] on the rights of BD as a holder of Common Stock: (i) effecting any
Deemed Liquidation Event; (ii) amending, altering or repealing any provision of the Charter, the bylaws of Cytek, or the Voting Agreement; (iii) reclassifying, altering or amending any Common Stock in respect of the distribution of assets
on the liquidation, dissolution or winding-up of Cytek, the payment of dividends, or rights of redemption; or (iv) effecting any recapitalization or redemption of its Common Stock that results in other
holders of Common Stock receiving consideration per share with respect to the Other Common Shares that is [***] For the avoidance of doubt, so long as no holders of shares of Common Stock receive or are entitled to receive consideration or
preference on a per share basis or in consideration of or to offset any decrease in the value of the Common Stock that is not offered to all holders of Common Stock in connection with such action or change, (i) any action that adversely affects
the shares of Common Stock as a class or (ii) any change in voting rights whereby certain holders of Common Stock may have more voting power than other holders of Common Stock (if weighted voting rights are implemented by the Company), in each
case shall [***] with respect to the rights of the BD Shares. 

  
 13 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT
IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 
  

	13.3	 Voting Agreement. On the Effective Date, BD shall deliver to Cytek (i) an executed Adoption
Agreement (as defined in the Voting Agreement), agreeing to be bound by and subject to the terms of the Voting Agreement as a “Stockholder” thereunder. Notwithstanding anything to the contrary contained within the Voting Agreement,
the Voting Agreement may not be amended, modified or terminated, and no provision thereof may be waived, in each case with respect to BD if such amendment, modification, termination or waiver materially and adversely affects BD in a different and
disproportionate manner relative to the other similarly situated Stockholders thereunder, unless such amendment is agreed to in writing by BD. 

  

	13.4	 Notice of Certain Events. Cytek shall provide notice to BD at least [***] days in advance of taking any
of the following actions: 

  

	 	(a)	 effect any reclassification, exchange, combination, substitution, reorganization or recapitalization of the
outstanding shares of the Common Stock; 

  

	 	(b)	 effect a Deemed Liquidation Event (as defined in the Charter) or to liquidate, dissolve or wind up its business
or affairs; or 

  

	 	(c)	 effect Cytek’s first underwritten public offering of its Common Stock under the Securities Act of 1933, as
amended. 

 ARTICLE 14 

MISCELLANEOUS PROVISIONS 
  

	14.1	 No Other Rights. No other rights, immunities, or licenses are granted hereunder, by implication,
estoppel, statute or otherwise, except as expressly provided in this Agreement. 

  

	14.2	 Assignment by BD. This Agreement is assignable by BD to any Affiliate of BD or any successor to its
business and operations to which this Agreement relates, without the consent of Cytek, provided that BD shall notify Cytek at least [***] prior to any such assignment. 

 

	14.3	 Assignment by Cytek. This Agreement is assignable by Cytek to any Affiliate of Cytek or any successor to
its business and operations, or in connection with a transaction for the sale of all or substantially all of the stock or asset to which this Agreement pertains, in each case without the written consent of BD, provided that Cytek shall notify BD at
least [***] prior to any such assignment. 

  
 14 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT
IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 
  

	14.4	 Successors and Assigns. This agreement shall be binding upon and inure to the benefit of the Parties and
their respective successors and permitted assigns. 

  

	14.5	 Assignment of Covered Patents. Subject to the provisions of Section 3.1, the Covenant Not to Sue
contained herein shall run with each BD Patent and shall be binding on any successor-in-interest or assignee thereof with respect to such BD Patent. BD shall not assign,
or grant any exclusive license under, any such BD Patent to any Third Party unless such assignment or grant of exclusive license is subject to the Covenant Not to Sue granted under this Agreement with respect to such BD Patent that was assigned.

  

	14.6	 Waiver. Either Party’s waiver of any term of condition of this Agreement at any time shall not be
construed to waive such term or condition at subsequent times or any other term or condition, nor as a waiver of its rights to enforce such term or condition. 

 

	14.7	 Joint Drafting; Interpretation. The Parties have participated jointly in negotiating and drafting this
Agreement. If any ambiguity, question of intent or question of interpretation arises with respect to this Agreement, then this Agreement will be construed as if drafted jointly by the Parties, and no presumption or burden of proof will arise
favoring or disfavoring any Party by virtue of the actual or alleged authorship of any of the provisions of this Agreement. The term “including” shall mean “including, without limitation.” 

 

	14.8	 Governing Law. This Agreement and matters connected with the performance thereof shall be construed,
interpreted, applied and governed in all respects in accordance with the laws of Delaware, without reference to conflict of laws principles. 

  

	14.9	 Headings. The headings and subheadings herein are inserted for the convenience of reference only and
shall not affect the interpretation of this Agreement. 

  

	14.10	 License Survival During Bankruptcy. All rights and licenses granted under or pursuant to this Agreement
are, and will otherwise be deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code, licenses of rights to “intellectual property” as defined under Section 101(35A) of the U.S. Bankruptcy Code. Each Party
further acknowledges and agrees that if a Party (or any other Person to which such Party has assigned this Agreement or any BD Patents, as applicable), as a debtor in possession or a
trustee-in-bankruptcy in a case under the U.S. Bankruptcy Code, rejects this Agreement, each of the other Parties may elect to retain its rights under this Agreement as
provided in Section 365(n) of the U.S. Bankruptcy Code. Without limiting the foregoing, the Parties acknowledge that the rights, licenses, and releases granted pursuant to this Agreement, to the maximum extent permitted by law, will not be
affected by the rejection of this Agreement in bankruptcy, and will continue to be subject to the terms and conditions of this Agreement. In the event that this Agreement is rejected or deemed rejected in a bankruptcy proceeding (a
“Rejection”), the debtor Party will provide written notice thereof to the non-debtor Party. To the extent any rights under this Agreement are determined by a bankruptcy court not to be
“intellectual property” rights for purposes of Section 365(n) of the U. S. Bankruptcy Code, all of such rights will remain vested in and fully retained by the non-debtor Party after any
such Rejection. 

  

	14.11	 Notice. Any notice hereunder shall be in writing and shall be sent by a reliable overnight courier
service; by prepaid registered or certified mail, return receipt requested; or by email (with hard copy sent via another method permitted in this Section 14.11 on the same day) to another Party at the address or email address below or to such
other address or email address for which such Party shall give notice hereunder. Such notice shall be deemed to have been given one day after the date of sending if by overnight courier service, or five days after the date of sending by registered
or certified mail, or upon confirmed receipt if delivered by email, excepted that notice of change of address shall be effective only upon receipt. All communications and notices to be made or given pursuant to this Agreement shall be in the English
language. 

  
 15 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT
IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 
  

 If to BD: 

Becton, Dickinson and Company 

Attn: Sam Khichi 

1 Becton Drive 

Franklin Lakes, New Jersey 07417 

United States of America 

Email: [***] 

Phone: [***] 

with copy to: 

Becton, Dickinson and Company 

Attn: BD Biosciences Business Unit President 

2350 Qume Drive 

San Jose, California 95131 

United States of America 

Email: [***] 

Phone: [***] 
 If
to Cytek: 
 Cytek Biosciences Inc. 

Attn: Wenbin Jiang 

46107 Landing Pkwy 

Fremont, California 94538 

United States of America 

Email: [***] 

Phone: [***] 

with copy to: 

Cooley LLP 

Attn: Gordon Ho 

3175 Hanover Street 

Palo Alto, California 94304 

United States of America 

Email: [***] 

Phone: [***] 
  

	14.12	 Further Assurance. Each Party agrees to enter into and execute such additional documents and instruments
and to take such other actions as may be reasonably necessary to implement the purposes and intentions of this Agreement. 

  

	14.13	 Severability. If any provision of this Agreement is held to be unenforceable for any reason, it shall be
adjusted rather than voided, if possible, in order to achieve the intent of the Parties to the extent possible. In any event, all other provisions of this Agreement shall be deemed valid and enforceable to the fullest extent possible.

  

	14.14	 Entire Agreement. This Agreement contains the entire agreement between the Parties and supersedes all
previous written or oral negotiations, commitments, transactions, or undertakings with respect to the subject matter hereof. The parties expressly agree, promise and acknowledge that they have not relied on any previous written or oral negotiations,
commitments, transactions, or undertakings with respect to the subject matter hereof, but have based their decision to enter this Agreement solely on the terms expressed in writing herein. This Agreement may be modified only in writing, executed by
duly constituted officers of both Parties. 

  
 16 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT
IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 
  

	14.15	 Counterparts. This Agreement may be executed in counterparts, one signed by each Party hereto, each of
which shall be deemed an original, but all of which together constitute the same singular effective instrument, and which shall become effective as of the Effective Date when executed by the last Party hereto. 

(The remainder of this page has been intentionally left blank. The signature page follows.) 

  
 17 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT
IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 
  

 IN WITNESS WHEREOF, the Parties do hereby execute this Settlement, License and Equity
Issuance Agreement by duly authorized officials to be effective as of the Effective Date: 
  

									
	Becton, Dickinson and Company	 		 	Cytek Biosciences Inc.
					
	By:	 	/s/ Puneet Sarin	 		 	By:	 	/s/ Wenbin Jiang
	Name:	 	Puneet Sarin	 		 	Name:	 	Wenbin Jiang
	Title:	 	President – BD Biosciences	 		 	Title:	 	Chief Executive Officer

  
 18 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT
IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 
  

 Exhibit A 

Hardware and Software Configurations of Current Cytek Instruments 

 

					
	 Cytek Current Instrument:
  

[***]
  

[***]
  

[***]
	  	 Specification:
  

[***] brochure
  

[***] brochure
  

[***] brochure
	  	 Software Versions:
  

[***]
  

[***]
  

[***]
  

[***]
  

[***]
  

[***]

  
 19 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT
IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 
  

 Appendix A-1 

[***] brochure 

  
 20 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT
IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 
  

 Exhibit B 

Form of Dismissal of Litigation 

  
 21 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT
IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 
  

 UNITED STATES DISTRICT COURT 

NORTHERN DISTRICT OF CALIFORNIA 

SAN FRANCISCO DIVISION 
 ROPES &
GRAY LLP 
 James R. Batchelder (CSB # 136347) 
 David S. Chun
(CSB # 315958) 
 Daniel W. Richards (CSB # 280595) 
 1900
University Ave. Sixth Floor 
 East Palo Alto, CA 94303-2284 

Tel: (650) 617-4000 

james.batchelder@ropesgray.com 
 david.chun@ropesgray.com 

daniel.richards@ropesgray.com 
 Attorneys for Plaintiff
Becton, Dickinson and Company 
 [See signature page for complete list of parties represented] 

 

					
	 BECTON, DICKINSON AND COMPANY,

 
 Plaintiff / Counterclaim-Defendant v.

 
 CYTEK BIOSCIENCES INC., MING YAN, ALFRED RILEY, DAVID VRANE, ZHENYU
ZHANG, ZHENXIANG GONG, ALEX ZHONG, MARIA JAIMES, GIL REININ, and JANELLE SHOOK,
  

Defendants / Counterclaim-Plaintiff.
  
	 	)
 )
 )

)
 )

)
 )

)
 )

)
	  	 C.A. No.
3:18-cv-00933-MMC
  

JOINT STIPULATION AND ORDER FOR DISMISSAL WITH PREJUDICE AND PROPOSED ORDER

  
 22 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT
IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 
  

 STIPULATION 

The parties to this action, acting through counsel, and pursuant to Federal Rule of Civil Procedure 41(a)(1)(A)(ii) hereby stipulate, in
consideration of a negotiated settlement executed by them, to the Dismissal With Prejudice of this action, including all claims and counterclaims stated therein against all parties, with each party to bear its own attorney’s fees and costs.

 IT IS SO STIPULATED 
 October
    , 2020 
 Respectfully submitted, 

  
 23 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT
IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 
  

			
		
	/s/
                                         
                       	  	/s/
                                         
                       
	 ROPES & GRAY LLP
 James R.
Batchelder (CSB # 136347)
 David S. Chun (CSB # 315958)
 Daniel
W. Richards (CSB # 280595)
 1900 University Ave. Sixth Floor East Palo

Alto, CA 94303-2284
 Tel: (650)
617-4000
 Fax: (650) 617-4090

james.batchelder@ropesgray.com
 david.chun@ropesgray.com

daniel.richards@ropesgray.com
  

Mark S. Popofsky (CSB # 175476)
 Anne Johnson Palmer (CSB #
302235)
 ROPES & GRAY LLP
 Three Embarcadero
Center
 San Francisco, CA 94111-4006
 Tel: (415) 315-6300
 Fax: (415) 315-6350

mark.popofsky@ropesgray.com
anne.johnsonpalmer@ropesgray.com
  

Peter M. Brody (pro hac vice)
 2099 Pennsylvania Ave.
NW
 Washington, DC 20006-6807
 Tel: (202) 508-4600
 Fax: (202) 508-4650

peter.brody@ropesgray.com
	  	 COOLEY LLP
 STEPHEN C. NEAL (170085)

(sneal@cooley.com)
 JEFFREY S. KARR (186372)

(jkarr@cooley.com)
 MATTHEW E. BUCCELLATO (296079)

(mbuccellato@cooley.com)
 3175 Hanover Street

Palo Alto, CA 94304-1130
 Telephone:  (650) 843-5000
 Facsimile:   (650) 849-7400

 
 MARTIN S. SCHENKER (109828)

(mschenker@cooley.com)
 101 California Street, 5th Floor

San Francisco, CA 94111-5800
 Telephone:  (415) 693-2000
 Facsimile:   (415) 693-2222

 
 ADAM S. GERSHENSON (pro hac vice)
(agershenson@cooley.com)

DANE R. VORIS (281051)
 (dvoris@cooley.com)

500 Boylston Street, 14th Floor Boston, MA 02116
 Telephone:
 (617) 937-2300
 Facsimile:   (617) 937-2400

 
 ROPERS, MAJESKI, KOHN & BENTLEY

TODD A. ROBERTS (129722)
 (todd.roberts@rmkb.com)

EDWIN B. BARNES (295454)
 (edwin.barnes@rmkb.com)

  
 24 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT
IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 
  

			
	 Kevin D. Sullivan (CSB # 270343)
 EPSTEIN
BECKER & GREEN, P.C.
 1925 Century Park East, Suite 500

Los Angeles, CA 90067
 Telephone: 310–556–8861

Facsimile: 310–553–2165
 ksullivan@ebglaw.com
	  	 1001 Marshall Street, Suite 500
 Redwood City,
CA 94063-2052
 Telephone: (650) 364-8200

Facsimile: (650) 780-1701
  

Attorneys for Defendant Cytek Biosciences Inc.

		  	/s/
                                         
                       
	Attorneys for Plaintiff Becton, Dickinson and Company	  	 ANDERIES & GOMES LLP
 Allan J.
Gomes (SBN 225810)
 Shane K. Anderies (SBN 215415)
 601
Montgomery St, Ste. 888
 San Francisco, CA 94111
 Telephone:
(415) 217-8802
 Fax: (415) 217-8803

agomes@andgolaw.com
 sanderies@andgolaw.com

 
 Attorneys for Defendants Ming Yan, Alfred Riley, David Vrane, Zhenyu Zhang,
Zhenxiang Gong, Alex Zhong, Maria Jaimes, Gil Reinin, and Janelle Shook

		
	PURSUANT TO STIPULATION, IT IS SO ORDERED.	  	
		  	  

	Date:                     , 2020	  	HON. MAXINE CHESNEY UNITED STATES DISTRICT JUDGE

  
 25 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT
IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 
  

 ECF ATTESTATION 

I, James R. Batchelder, am the ECF User whose ID and password are being to file this JOINT STIPULATION AND ORDER FOR DISMISSAL WITH PREJUDICE
AND PROPOSED ORDER. In compliance with Civil Local Rule 5-1(i)(3), I attest that concurrence in this stipulation has been obtained from any signatories indicated by a “conformed” signature (/s/)
within this e-filed document. 
  

			
	 Dated: October     , 2020
	  	
/s/                  
                                         
     

  
 26 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT
IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 
  

 Exhibit C 

Destruction of BD Confidential Documents 

  
 27 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT
IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 
  

 Exhibit D 

Compliance Certification Form 

  
 28 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT
IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 
  

 CERTIFICATE OF COMPLIANCE WITH 

DESTRUCTION OF BD CONFIDENTIAL DOCUMENTS 

dated as of         , 20 

I, the undersigned individual, hereby represent and certify on behalf of Cytek Biosciences Inc., a Delaware corporation having a place of
business at 46107 Landing Parkway, Fremont, California 94538 (“Cytek”) to Becton, Dickinson and Company, a New Jersey corporation having a place of business at 1 Becton Drive, Franklin Lakes, New Jersey 07417,
(“BD”) as set forth below. Defined terms (indicated by the use of initial capitalization) will have the meaning set forth herein, or if no meaning is set forth herein, will have the meaning set forth in the Settlement, License and
Equity Issuance Agreement that Cytek entered into with BD on October 5, 2020 (the “Agreement”). 
 As of the date
hereof, Cytek has complied with all of its obligations set forth in Section 2.3 of the Agreement. Without limiting the foregoing, I hereby declare under penalty of perjury that as of the date hereof that Cytek has destroyed and rendered
unrecoverable any and all documents identified in Exhibit C. 
 I do hereby execute, on behalf of Cytek, this Certificate of
Compliance with Destruction of BD Confidential Documents as of the day first written above. 
  

					
			
		 	Print name:	 	                                     
           
			
		 	Sign name:	 	                                     
           
			
		 	Address:	 	                                     
           
		
		 	                                   
                                   
			
		 	E-mail:	 	                                     
           
			
		 	Phone:	 	                                     
           

  
 29 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT
IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 
  

 Exhibit E 

Cytek Summary Capitalization Table 

  
 30 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT
IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 
  

 Exhibit F 

Cytek Certificate of Incorporation 

  
 31 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT
IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 
  

 Exhibit G 

Cytek Bylaws 

  
 32

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00330-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00330-of-00352.parquet"}]]